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Neuroendocrine axis and reproduction  
Introduction 
The physiology of the female reproductive system is regulated by a complex neuro-hormonal 
interaction whose operative center is the hypothalamus-pituitary-ovarian axis. 
The evidence that neurons poured into the general circulation biologically active substances 
(neurotransmitters and neuromodulators) represents the physio-anatomic substrate of the 
neuroendocrine complex as an integrated functional unit. The presence of structures in the nerve 
receptors for different hormones, capable, in their turn, to modulate the neuronal activity, reinforces 
this assumption.  
This delicate interplay is affected by external and internal stimuli that can alter its correct operation, 
deviating from physiology to pathology. 
This PhD thesis is based on the conduct of two lines of research focused on alterations in the 
hypothalamic-pituitary-gonad axis functioning. The two most common disorders of ovarian 
function, micropolycystic ovary syndrome (PCOS) and endometriosis, have been identified as 
models to assess the impact, on the axis, of endogenous and environmental variables, respectively. 
The first line of research has been focused on the hypothesis that the two main forms of clinical 
expression of PCOS, the strictly linked to hyperandrogenism and that one associated to insulin 
resistance, represent distinct disease entities and are, consequently, supported by different 
pathogenetic mechanisms. This hypothesis finds its origin on the fact that these two forms 
determine distinguishable endocrine and metabolic profiles. Nevertheless, there are no studies 
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investigating whether the PCOS phenotype differently alters the morphology gonads . On this basis, 
a clinical observational study has been conducted in PCOS women, aimed at evaluating the 
relationship between ultrasound pictures of polycystic ovaries and the endocrine-metabolic state of 
patients. 
The second line of research stems from the hypothesis of a possible role of environmental pollutants 
on another of the most common reproductive age pathologies: endometriosis. The disease affects 6-
10% of women and its exact etiology remains unknown. The possible role of toxic agents was 
proposed back in 1993 by Rier and collaborators and, since then, the interest in the impact on it of 
contaminants has been high. A systematic review of literature through electronic database was 
conducted without time restriction in order to analyze the relation between endometriosis and the 
most common environmental pollutants. 
The PhD thesis is organized in three chapters. The first two are aimed to report results from the 
main lines of research. A third chapter regards a parallel research experience that the PhD student 
started in the last year, during her fellowship at the University “Mangiagalli” of Milan (Italy). Each 
chapter is further divided in a first part concerning what‟s is known for any single topic and a 
second one dedicated to related studies done during the PhD. 
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Chapter I: The role of metabolic (endogenous) variables on the 
function of the gonadal axis: The PCOS model 
 
1. The Polycystic Ovary Syndrome 
 
1.a  Epidemiology, risk factors and main endocrine alterations 
Polycystic ovary syndrome (PCOS) is a common endocrine disease affecting approximately 5-10% 
of women of reproductive age (Consensus, Fertil Steril, 2008). This syndrome is considered a 
multifactorial disease and the individual susceptibility is probably determined by multiple genetic 
and environmental risk factors. The etiology of the syndrome remains obscure, and the variability in 
phenotype expression continues to render the clinical care and research concerning this 
heterogeneous condition challenging. 
Whatever the cause, the syndrome appears to be characterized by a wide variety of hormonal 
changes. 
We will analyze them individually. 
 
FSH deficiency 
In patients with PCOS we observe lower levels of serum FSH compared to women with normal 
ovulation. Although strongly reduced serum levels of FSH rarely occurs, it has been demonstrated 
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that, during PCOS, they are below the threshold required to stimulate maturation of the follicle. 
FSH suppression leads to a greater accumulation of antral follicles with diameter between 2 and 8 
mm. The mechanisms underlying the pathogenesis of this anomaly remain unknown. Nevertheless, 
there is an increasing body of evidence supporting the hypothesis of inherent differences in the 
mechanisms of folliculogenesis. Due to constantly reduced levels of FSH, folliculogenesis is 
obstructed and the growing follicles hesitate in liquid cysts. The premature end of growing follicles 
interferes with the dominant follicle selection process causing anovulation. 
 
Hypersecretion of LH 
Only in the 10-20% of women with a history of PCOS, the values of LH and FSH are normal. In the 
remaining portion, a significant increase in LH levels is observed since the early follicular phase. 
As a consequence, a reversal of the LH/FSH ratio occurs, which reaches values approximated at 
about 2.5. This phenomenon has to be found in different causes. First, regardless of the primary 
cause, in PCOS is observed hyperandrogenism; the increase in circulating androgens establishes a 
persistent positive feedback at pituitary level and, therefore, a maintenance of the hypersecretion of 
LH. Both factors are mutually reinforcing. In presence of a high concentrations of androgens, LH-
related suppression of estrogens and progesterone regulation of hypothalamic release of GnRH 
seem to be inhibited. Another possible cause is an increase in the pulses of GnRH at the 
hypothalamic level. This phenomenon is probably promoted by an interplay between androgens and 
some endogenous modulators and results in a significant increase in the amplitude and the 
frequency of the pulses of LH. 
Insulin also represents a chronic stimulus to LH production. In fact, It has a steroidogenic activity 
and it is able to synergize the action of LH on thecal cells, resulting in increase in the synthesis of 
androgens. 
The increase in LH levels during the folliculogenesis results in a suppression of FSH and 
consequent alteration of the function of the granulosa cells. In physiological conditions, the 
granulosa cells are sensitive to LH only when the follicle has reached a diameter of about 9-10 mm. 
In contrast, in women with PCOS, this response is anticipated, involving also small follicles of 
about 4 mm. Therefore an early luteinization and the atresia of small follicles occur.  
The final effect is the premature maturation of oocytes with  chronic anovulation. 
 
Hyperandrogenism 
Hyperandrogenism is the most common endocrine abnormality in PCOS, involving 60-80% of 
women affected. The major circulating androgens are essentially produced by two separate sources: 
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the ovary and the adrenal gland. The ovary is the main source of androstenedione and testosterone, 
and the adrenal gland produces mainly Dehydroepiandrosterone sulfate (DHEA-S) as well as 
testosterone. 
The multiple effects of androgen hormones are due to the free part, namely that is not linked to Sex 
Hormone Binding Globulin (SHBG), a plasma protein produced in the liver. The circulating 
androgens derive either directly from an increase of the ovarian biosynthesis either by a reduction 
of SHBG, as it often happens in patients with insulin-resistance. The same androgens reduce SHBG 
with direct mechanism. The increased concentration of androgens in the follicular fluid is associated 
with increased serum levels of LH, which may help to stop the development of the dominant follicle 
leading to block and degeneration. It is also suggested that high levels of androgens have a negative 
effect on the development of oocyte competence. This phenomenon is determinant in the 
establishment of a condition of chronic anovulation. 
The high concentrations of testosterone at the peripheral level make it available for its 
transformation to dihydrotestosterone, which is the biologically most effective hormone. This 
conversion is performed by the 5-alpha reductase, which is especially expressed at the cutaneous 
level. The result is an increased hair growth at the level of normally hairless regions like face, breast 
areola, linea alba and back. 
 
1.b Diagnostic criteria  
Proposed diagnosed criteria for PCOS include the NIH Consensus, in 1990, that defined it as the 
presence of clinical and/or biochemical hyperandrogenism and oligomenorrhea/anovulation. Later, 
in 2003, the Rotterdam Consensus (Fauser et al., 2012) introduced the polycystic ovary appearance 
(PCO) on ultrasound as a new criterion to be added to the two previous criteria of the NIH, and the 
diagnosis requires two out of these three criteria. In turn, the Androgen Excess and PCOS Society 
considered that androgen excess is a central event in the pathogenesis and development of PCOS, 
and established that this criterion should be present and accompanied by one of the others: 
oligomenorrhea and/or PCO. In all cases, exclusion of other androgen excess disorders, such as 
non-classical congenital adrenal hyperplasia (NC-CAH), Cushing‟s syndrome, androgen-secreting 
tumors, hyperprolactinemia, thyroid diseases, drug-induced androgen excess, should be excluded, 
as well as other causes of oligomenorrhea or anovulation. 
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TAB 1 DIAGNOSTIC CRITERIA FOR PCOS. 
  
In consequence, new phenotypes have arisen in addition to the classic phenotype, in which patients 
present hyperandrogenism and oligomenorrhea with or without PCO on ultrasound. These new 
phenotypes are the “ovulatory phenotype”, which means hyperandrogenism and PCO in an 
ovulatory woman, and the “non-hyperandrogenic phenotype”, in which there is oligomenorrhea and 
PCO, without overt hyperandrogenism. Anti-Müllerian Hormone (AMH) levels are correlated with 
follicle counts and its measurement has been useful for screening and prognosis of reproductive 
issues. The determination of an AMH cutoff value is still lacking, but may become an additional 
tool to define PCO and PCOS phenotypes in the near future. In turn, morphological ovarian changes 
are not exclusive of PCOS, and the presence of PCO in no hirsute women with normal cycles is not 
negligible, varying from 2.5 to 33% in different studies. In addition, while the inclusion of a non-
hyperandrogenic phenotype of the diagnosis of PCOS is still controversial, some authors consider 
the presence of PCO as being itself a sign of hyperandrogenism. Recently, an Expert Panel from a 
NIH Evidence-Based Methodology Workshop on PCOS reinforced the use of the wider Rotterdam 
Criteria to diagnose the Syndrome. Classic PCOS is the most common phenotype, with a 
prevalence of around 70%, with the ovulatory and the non-androgenic phenotypes sharing the other 
30% of prevalence. Clinical characterization also changes throughout the lifespan, especially during 
the post-menarche years and in the menopause transition. 
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TAB 2 PCOS PHENOTYPES. 
 
 
Analyzing these criteria it‟s clear that the scientific community didn‟t take into consideration the 
main endocrine alterations typical of PCOS. In particular, the alterations that involve the 
neuroendocrine axis, such as LH hypersecretion, and the metabolic features do not appear either in 
the form of minor criteria. 
So it should be stressed that the choice of the individual laboratory tests and instrumental 
investigations should be personalized and remains subject to a proper medical history framework 
and a complete physical examination. 
 
Chronic anovulation   
The first aspect that should be considered in the diagnostic evaluation of a patient with suspected 
PCOS is anovulation.  
To validate the presence of ovulation we use ultrasound and hormonal investigations. Through 
serial sonograms, repeated at regular intervals, you can evaluate follicle growth and changes that 
occur in endometrium. The hormonal dosages, on the other hand, are performed to check that 
corresponds to the adequate follicular growth hormone production. The dosage of progesterone, to 
be carried out around the 20-25th day of the cycle, according to ultrasonographic evidence, appears 
to be diriment for the diagnosis of occurrence of ovulation: levels greater than 5 ng/ml confirm this 
phenomenon. Before the 14th day can be indicated the detection of serum E2 and LH in order to 
assess the presence of the pre-ovulatory peak. 
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Hyperandrogenism 
The second aspect is clinical and biochemical hyperandrogenism. 
It‟s important to measure hormones in early follicular phase. Elevated free Testosterone (T) levels 
are observed in approximately 70% of PCOS patients. The vast majority of the abnormal values are 
in the form of free T, with the sole measurement of total T adding little to the diagnosis. The present 
recommendation is to measure free T concentration either directly by equilibrium dialysis, or to 
calculate free T based on the total T measured accurately (by RIA using column chromatography, or 
by LC-MS or GC-MS) and SHBG (measured using competitive binding or a high quality immune-
based assay). The value of measuring Androstenedione is unclear, but it may increase the number of 
subjects identified as hyperandrogenic by 10%. Approximately 20% to 30% of patients with PCOS 
will demonstrate abnormal levels of DHEAS, which may be the only abnormality in circulating 
androgens in 10% of these patients. Nonetheless, we should note that DHEAS levels might not 
always reflect the status of adrenocortical steroidogenesis, and over interpretation of DHEAS levels 
should be avoided. Circulating levels of DHEA have limited diagnostic value. Serum measurements 
of androgens, including free T, should be used only as an adjuvant tool for the diagnosis of 
hyperandrogenic disorders, and never as the sole criterion for diagnosis or in lieu of the clinical 
assessment. This latter recommendation reflects the fact that between 20% and 40% of women with 
PCOS will have androgen levels within the „„normal‟‟ range, and assays for androgens, particularly 
total T, are highly variable and inaccurate.  
Clinical features of hyperandrogenism frequently seen in PCOS include hirsutism, acne, and 
androgenic alopecia. 
Hirsutism is the presence of terminal hairs on the face and/or body in a female in a male-type 
pattern. The most common method of determining the presence of hirsutism uses a visual score. 
Various methods have been proposed. The most commonly used method is a modification of a 
method originally reported by Ferriman and Gallwey. Nine body areas, including the upper lip, 
chin, chest, upper back, lower back, upper and lower abdomen, upper arm, and thigh, are assigned a 
score of 0–4 based on the density of terminal hairs. A score of 0 represented the absence of terminal 
hair, a score of 1 minimally evident terminal hair growth, and a score of 4 extensive terminal hair 
growth. The cutoff value should be established after the study of a large population of unselected 
women. Using this approach, cutoff values for defining hirsutism have been variously reported to be 
a score of 6 or greater, 7 or more, and 8 or more. Overall, hirsutism is an important feature of 
PCOS, affecting approximately 65% to 75% of patients with PCOS, including women of White, 
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Black, and Southeast Asian race. The prevalence of hirsutism in PCOS is likely to be less among 
women of East Asian extraction. 
Fig.1 Ferriman and Gallwey score 
 
Acne affects approximately 12% to 14% of White PCOS patients although the prevalence of this 
dermatologic abnormality varies with ethnicity: it is reportedly higher in Asian Indians and lower in 
Pacific Islanders it is unclear whether the prevalence of acne is significantly increased in these 
patients over that observed in the general population. 
Scalp hair loss in women is a distressing complaint with significant psycho logic morbidity. It 
usually represents the pilosebaceous unit response to endogenous androgens and may be associated 
with acne and hirsutism. Androgen sensitivity of the pilosebaceous unit varies, and there is poor 
correlation between clinical features and evidence of biochemical hyperandrogenism. The presence 
of DHT, formed from the 5a-reduction of the dermal papilla, is associated with a higher 5a-
reductase activity in the hairs plucked from a scalp presenting with androgenic alopecia. In addition 
to androgen excess, other potential etiologies of alopecia or diffuse scalp hair loss in any woman 
may be genetic (familial premature scalp follicular loss), environmental (damage following the use 
or abuse of hair cosmetics), and nutritional (e.g., poor protein intake, zinc deficiency, iron-deficient 
anemia). Androgenic alopecia is a recognized sign of PCOS. However, the prevalence of this 
abnormality in PCOS is unclear. The pattern of hair loss in PCOS generally involves thinning of the 
crown with preservation of the anterior hairline. Androgenic related alopecia in women with PCOS 
tends to be seen in the anterior midvertex area extending to the crown. The anterior hairline remains 
intact in women with PCOS and significant a bitemporal scalp hair recession is unusual except in 
virilizing syndromes. The only presence of alopecia or diffuse scalp hair loss in women may be the 
only dermatologic sign of PCOS. However, estimates regarding the prevalence of alopecia in PCOS 
vary widely, from 5% to 50%, and further studies are needed to better define this prevalence.  
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In addition to PCOS, there are numerous other disorders of androgen excess in women, including 
the adrenal hyperplasia (CAHs), syndromes of severe insulin resistance, and androgen- secreting 
neoplasms (ASNs); and disorders that have not been well identified (e.g., idiopathic 
hyperandrogenism) or that have the appearance of androgen excess (e.g., idiopathic hirsutism). 
These disorders account for approximately 10% to 30% of all patients with androgen excess. There 
are also a number of other disorders that may result in ovulatory dysfunction, including 
hyperprolactinemia and thyroid abnormalities. Consequently, although PCOS has specific 
diagnostic criteria, other disorders associated with androgen excess and/or menstrual irregularities 
should be excluded. First of all it is important to assess serum levels of testosterone. In the presence 
of concentrations greater than 2 ng/ml it is possible to suspect a disease of neoplastic origin, 
especially when the condition of hyperandrogenism is established in a short time (2-6 months). To 
rule out congenital adrenogenitale syndrome, linked to enzyme deficiency primarily of 21-
hydroxylase, it must be taken into account that it manifests in prepuberal age and usually is 
associated with signs of virilization, while in adrenogenitale acquired immune deficiency syndrome, 
due to adrenal-secreting tumors, the picture clinical manifests itself in extremely short times. In 
differential diagnosis, it is important the dosage of 17-OH progesterone. Normally the 17-OH 
progesterone of ovarian origin tends to increase during the second phase of the menstrual cycle as it 
is synthesized by the corpus luteum. Although the hormone frequently appears higher in patients 
with PCOS, the detection of values above 200 ng/dL, in the follicular phase, justifies diagnostic 
exams necessary to rule out alternative endocrine dysfunction such as adrenal hyperplasia. In these 
cases, it is indicated to perform a stimulation test with ACTH.  
 
Ultrasound pattern  
The third criterion considered in the Consensus Conference of Rotterdam is the ultrasound pattern 
of the ovary.  
According to the actual recommendations, the criteria that have high sensibility and specificity to 
define the presence of PCOS are: 
- an ovarian volume >10 cm3 ; 
- 12 or more follicles; 
-  Follicles diameter of 2-9 mm. 
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Taking into account only the indications of Rotterdam Consensus Conference, it‟s evident that the 
ultrasound diagnosis considers only the valuation of ovarian volume and the number of follicles. 
Individual variables such as the follicles distributions, the stroma expansion and vascular 
characteristics of the organ are excluded.  
The classic aspect of a polycystic ovary is represented by a predominantly elongated body shape 
and with plenty of stroma in the intrathecal region; the follicles visible on ultrasound as a hypo-
anechoic areas with a round shape, are found mainly on the outskirts of the organ and are arranged 
according to an architecture defined by some authors as "necklace" or "string of pearls". Even the 
presence of a single ovary with these features allows the diagnosis of PCOS.  
In the attempt to increase the diagnostic efficacy of ultrasound, Fulghesu et al. (2001) have 
proposed the enlarged ovarian stroma as a marker of PCOS (Pache et al., 1992; Dewailly et al., 
1994) . The stroma/total area (S/A) has a sensitivity of 100% and is highly correlated with plasma 
androgen level
5
. It‟s considered positive, for the morphological diagnosis, a cut-off of 0,34.  
The coexistence of different criteria and the continuous research for ultrasound parameters reflect 
the climate of uncertainty and the need to identify new ways to increase the sensitivity of ultrasound 
diagnosis. 
 
1.c  Metabolic alterations 
Obesity is a prevalent characteristic of PCOS, ranging from 12.5% to 100%, with a pooled 
estimated prevalence of 49%, as shown by a recent meta-analysis. The presence of obesity may 
exacerbate the metabolic and reproductive disorders associated with the syndrome, including insulin 
resistance, dyslipidemia and metabolic syndrome. A meta-analysis has shown that women with 
PCOS have higher levels of triglycerides (TG), LDLcholesterol and total cholesterol (TC), and 
lower HDLcholesterol levels compared with control women, regardless of body mass index (BMI). 
In addition, PCOS women present higher risk for type 2 diabetes. PCOS is also associated with a 
clustering of cardiovascular risk factors. However, there is no definitive evidence for increased 
cardiovascular events, or data showing that PCOS alone leads to increased cardiovascular risk 
independent of associated risk factors. In fact, more rigorous cohort studies of long-term 
cardiovascular outcomes and clinical trials of risk factor modification are required for women with 
PCOS.  
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2 The Ultrasonographic findings related to insulin resistance in patients with 
polycystic ovarian syndrome: a retrospective observational study 
 
2.a  Scientific BACKGROUND 
Although insulin resistance is found in a high percentage of women affected by PCOS (Diamanti-
Kandarakis et al., 2012),
 
neither hyperinsulinism nor the metabolic syndrome are among the 
diagnostic criteria for PCOS established by the Rotterdam Consensus Group (Revised 2003 
consensus, Fertil Steril, 2004). Furthermore, the diagnostic criteria for insulin resistance are much 
debated.  
There is evidence that the pathogenic mechanisms of insulin resistance-related PCOS differs from 
those underlying hyperandrogenism (Diamanti-Kandarakis et al., 2012; Diamanti-Kandarakis et al., 
2006). This assumption has allowed to identify two distinct PCOS phenotypes: one more strictly 
due to hyperandrogenism and a second where insulin resistance plays a crucial pathogenetic role. 
Currently, the "gold standard" procedure for the diagnosis of insulin resistance is the euglycemic 
clamp together with the so-called "minimal model". A less time-consuming method is homeostasis 
model assessment (HOMA). It has been demonstrated that the co-presence of increased HOMA and 
alterations of anthropometric parameters (body mass index [BMI] and the waist-to-hip ratio 
[WHR]) has high accuracy in predicting abnormal “minimal model” and can be adopted, in the 
clinical practice, as reliable method of diagnosis (Ciampelli et al., 2005).  
According to Rotterdam Criteria, polycystic appearance of the ovary is diagnosed when more than 
12 follicles and/or a volume >10 ml is detected in at least one gonad. Nevertheless, no clear 
identification of different morphologic patterns is considered. It could be argued that, if 
hyperandrogenism and hyperinsulinism affect folliculogenesis throughout different pathogenic 
pathways,  a difference in the size and distribution of atretic follicles may occur. This issue has 
never addressed before, where no distinction between ultrasound ovarian pattern in this two 
different PCOS phenotypes has been reported. The aim of the retrospective observational study was 
to assess the impact of insulin resistance on ovarian ultrasonographic parameters in patients with 
PCOS. 
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2.b  Patients and Methods 
Patients 
We evaluated PCOS patients who fulfilled Rotterdam criteria (Revised 2003 Consensus, Fertil 
Steril, 2004, attending the clinics of Endocrinology of Reproduction and Sterility-Infertility of our 
Department from January 2013 to December 2015. Given the observational and retrospective 
character of this study, Ethics Committee approval was not required. Inclusion criteria were signs of 
polycystic ovaries, according to the most recent ESHRE/ASRM consensus criteria (Fauser et al., 
2012; Balen et al., 2003) . Exclusion criteria were: basal follicle stimulating hormone (FSH) >10 
IU/l; administration of estro-progestin or other hormonal treatment in the previous six months; 
congenital adrenal hyperplasia and other endocrine abnormalities; presence of ovarian formations 
with diameters >14 mm in two ultrasound examinations carried at an interval of 30 days; thyroid 
disorders; diabetes mellitus; presence of a single ovary; and previous ovary surgery. 
The patients anthropometric characteristics (weight, height, BMI and WHR) were collected as well 
as serum levels of gonadotrophins, DHEA-S and free testosterone measured in the early follicular 
phase. We also evaluated hirsutism with the Ferriman-Gallwey clinical score. All enrolled subjects 
underwent a 75-g oral glucose challenge and insulin measurements at baseline and 60, 120 and 180 
minutes thereafter. Insulin resistance was diagnosed only when all the following criteria were 
fulfilled: HOMA >2.5 (Ciampelli et al., 2005); BMI >27 kg/m
2
; WHR >0.85 (Qiao et al., 2010); 
sex hormone binding globulin (SHBG) serum levels below the 25th percentile (Ciampelli et al., 
2005; Qiao et al., 2010) and serum insulin >150 IU/ml at 60 min and a change <20% between 60 
and 120 min after oral glucose load with 75 g of glucose (Matsuda et al., 1999). Based on these 
parameters, we identified a group of patients with insulin resistance (group 1) and a group without 
insulin resistance (group 2). We did not evaluate patients with intermediate metabolic conditions, 
namely those who did not fulfill all the criteria. 
 
Ultrasound parameters  
Pelvic ultrasound examination was carried out with a 6.5 MHz vaginal probe. The external 
circumference of the ovary and the stroma were measured to determine the S/A ratio (Figure 2). 
The following sonographic parameters were recorded for each patient: total number of ovarian 
follicles with a diameter <10 mm; number of follicles with diameter between 2 and 4 mm; the S/A 
ratio calculated with an ovarian median scan (Fulghesu et al., 2001); and ovarian longitudinal (A), 
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transverse (B) and coronal (C) diameters and volume (1/2 x [A x B x C]) (Fulghesu et al., 2007). 
Based on these parameters, we arbitrarily defined two ultrasound patterns (Figures 3 and 4): type A, 
characterized by >50% follicles with diameters between 5 and 9 mm and with an S/A >0.34 
(“necklace” sign defined by a hyperechoic central area and a rosary-like peripheral disposition of 
follicles); and type B, characterized by >50%  follicles measuring 2-4 mm and with an S/A ≤0.34 
(no "necklace" sign and ubiquitously distributed follicles). Intermediate ultrasound patterns were 
not included in our analysis.  
 
Statistical analysis 
Results are reported as means ± standard deviation (SD). The student T test or the Mann-Whitney U 
test were used for continuous variables with a parametric or not parametric distribution, 
respectively. Normal distribution of continuous variables was evaluated with the Shapiro test. 
Cohen‟s kappa was used to evaluate the agreement between sonographers with respect to ultrasound 
ovarian pattern. Sensitivity, specificity, positive predictive value, negative predictive value, positive 
and negative likelihood ratio were calculated with the MedCalc statistic software to assess the 
accuracy of an ultrasound pattern in identifying PCOS patients with insulin resistance. The 
2 
test 
was used to compare categorical data. A p <0.05 was considered statistically significant. The SPSS, 
statistical software 18.0 (SPSS Inc., USA) was used to analyze data. 
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2.c  Results 
Of the 309 patients affected by PCOS admitted to our institute between December 2010 and 
December 2013, only women without an intermediate ultrasound profile and fulfilling the 
Rotterdam criteria for PCOS were included for a total of 78 patients enrolled (Figure 2). Forty-one 
of these women met all the criteria of insulin resistance (group 1); the remaining 32 patients did not 
fulfill any insulin resistance criterion (group 2). Woman with an intermediate metabolic profile 
were not included in our analysis (Figure 2). Demographic, anthropometric, hormonal and 
ultrasound features of the two groups stratified according to insulin resistance are listed in Table 1. 
There was no difference in terms of age, androgen levels or Ferriman-Gallwey score between the 
two groups. Women affected by insulin resistance were more likely to have a type B ultrasound 
pattern than women without insulin resistance (36/41 87:8% versus 21.8%, p <0.01).  
The accuracy of the type B ultrasound pattern to identify PCOS women with insulin resistance was 
as follows: sensitivity 0.88 CI 95% (0.74–0.96 ); specificity 0.78 CI 95% (0.60–0.91), positive 
likelihood ratio 4.01 CI 95% (2.06–7.80), negative likelihood ratio 0.16 CI 95% (0.07–0.36); 
positive predictive value 0.84 CI 95% (0.69-93.2), negative predictive value 0.83 CI 95% (0.65-
0.94). A Cohen‟s kappa of 0.81, estimated in 50 subjects, indicated an excellent concordance 
between sonographers. 
A type A ovarian pattern was found in 33 women and the type B ovarian pattern in 45 women. The 
demographic, anthropometric and hormonal data of patients divided according the ultrasound 
pattern of PCOS are listed in Table 3. The mean age of patients, serum levels of gonadotropin, 
androgens and the Ferriman-Gallwey score did not differ significantly between the two groups. 
Conversely, BMI, WHR and HOMA values were significantly higher in patients with a B type 
ultrasound pattern. Patients with an A type pattern had higher SHBG levels (27.2 ± 11.3 nmol/l 
versus 52.2 ± 21.1 nmol/l, p < 0.01) and a larger ovarian volume (14.6 ± 5.6 versus 11.9 ± 4.1 cm
3
, 
p < 0.05) than did patients with an A type pattern.  
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2.d  Discussion 
This line of research has shown, for the first time, a variability in the morphological alterations of 
the ovaries in women with PCOS and that this heterogeneity is related to different expression of 
hyperandrogenic and hyperinsulinaemic components. This evidence strongly supports the 
hypothesis that, despite converging in apparently similar clinical features, diverse endogenous 
variables may differently alter the neuroendocrine-ovarian axis, reinforcing the idea that 
hyperandrogenic and metabolic phenotypes of the PCOS may be related to different pathogenic 
pathways. 
Body mass index, WHR and HOMA were significantly lower in patients with a type A ovary, 
namely those with the classical “necklace” sign, than in women with a type B ovary. A high HOMA 
related to elevated anthropometric indices was previously reported to be an efficient positive 
predictor of insulin resistance (Ciampelli et al., 2005). The association between insulin resistance 
and specific ultrasound patterns is supported by data obtained stratifying our study population into 
patients with insulin resistance (group 1) and patients without insulin resistance (group 2). Type B 
ovaries were significantly more frequent in group 1 than in group 2. On the contrary, the classic 
ultrasound picture of PCOS (type A) was more frequent in group 2 patients. Neither serum 
concentrations of androgens nor the Ferriman-Gallwey score differed between the two groups. 
However, all biochemical and clinical androgenic variables, including basal luteinizing hormone 
(LH), were higher in patients with a type A ovary than in those with a type B ovary, and the 
difference was almost significant in the case of 17-OH P concentrations (Table 3).  
The different ovarian profiles observed in this study support the concept that the pathogenesis and 
the clinical phenotype could differ between PCOS patients with hyperandrogenism and normal 
anthropometric parameters and PCOS patients with insulin resistance. In other words, two 
physiopathogenetic pathways, one characterized by hyperandrogenism and the other by insulin 
resistance, could induce the same effects. They could interfere with selection mechanisms of the 
dominant follicle and also induce atresia of secondary follicles. These folliculogenesis changes 
could result in anovulation, arrest of multiple follicles at different developmental stages and 
hyperandrogenism, which could be either primitive or secondary depending on clinical conditions.  
Based on the preliminary data, the classical ultrasound image characterized by a hyperechoic central 
area and a peripheral neck-lace arrangement of follicles is more typically observed in PCOS 
patients who have a more pronounced hyper-androgenic profile, minimal or absent insulin 
resistance and pronounced hypertricosis.  
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Ovarian morphology might change dramatically should the primum movens of PCOS development 
be insulin resistance. Normally, insulin, by way of the classic mechanism of “spill-over”, binds 
IGF-1 receptor thereby exerting mitogenic effects on the granulosa and theca. IGF-1 plays a pivotal 
role in the FSH-mediated proliferation of the granulosa, and it is hence important for the growth and 
development of follicles (Lucy et al., 2011). If the proliferation of antral follicles is not finely 
regulated, the mechanisms governing the selection of the dominant follicle could be deranged 
thereby fostering follicle atresia. Our data suggest that the growth of antral follicles is blocked 
before in PCOS women with insulin resistance. In fact, type B ovaries are characterized by a 
predominance of follicles with a diameter measuring between 2 and 4 mm. In addition, lack of 
prominent hyperandrogenism could explain absence of hyperthecosis, which in turn may lead to a 
ubiquitous distribution of follicles. Although insulin production could reduce SHBG concentrations 
and so it could lead to an increase in the free forms of various androgens particularly testosterone 
(Fauser et al., 2012), this effect does not seem sufficient to induce the hyperthecosis typical of 
PCOS associated with a hyperandrogenic pattern. These results support this hypothesis. In fact, 
androgen levels and clinical hyperandrogenism indices were lower in our patients with a type B 
ovary and partially in the hyperinsulinemic patients (Tables 3 and 4).  
The hypothesis that different PCOS profiles have specific physiopathological pathways may have 
important implications for the management of patients and might imply a revision of the current 
PCOS diagnostic criteria. In other words, the attempt of the Rotterdam Consensus Group (Revised 
2003 consensus, Fertil Steril, 2004) to define a shared, universal diagnosis of PCOS by gathering 
together patients with different characteristics and phenotypes may lead to a suboptimal approach 
for these patients even in fertility management. In detail, the insulinemic pattern seems to 
significantly influence ovarian response to gonadotropin administration(Ferorcsak et al., 2001) and 
ovarian drilling success (Amer et al., 2011). An increased risk of ovarian hyperstimulation 
syndrome in hyperinsulinemic patients has also been reported (Fulghesu et al., 1997). The insulin 
profile may also indirectly affect ovarian stimulation. In fact, insulin-sensitizing agents such as 
metformin before and during IVF/ICSI significantly reduced the incidence of ovarian 
hyperstimulation and improved the pregnancy rate (Tso et al., 2014). On the other hand, a 
hyperandrogenic profile may impair AMH production and lead to dysfunction of folliculogenesis 
(Eldar-Geva et al., 2005). The higher basal LH levels usually observed in hyperandrogenic women 
could also influence the ovarian response (Orvieto et al., 2012; Kumar et al., 2011). In detail, PCOS 
patients with an elevated LH/FSH ratio had a better pregnancy rate when treated with GnRH-
agonist protocols than with GnRH-antagonist protocols, probably because the long GnRH-agonist 
induces prolonged LH suppression milieu thereby avoiding the negative effect of higher LH levels 
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on reproductive outcome (Orvieto et al., 2012; Kumar et al., 2011; Homburg et al., 1988). 
Consequently, strategies that minimize the effect of LH could be considered for patients with a 
hyperandrogenic profile. 
2.e  Conclusion 
This line of research has used PCOS as a model of impact of endogenous variables on the gonadal 
axis. The result of the association between insulin resistance and a peculiar ultrasound pattern, in 
patients affected, demonstrate the important role of this metabolic alteration on the pathology and 
so on the neuroendocrine axis function. Besides this observation, if confirmed by larger studies, 
supports the concept that specific PCOS profiles could be identified by a complete metabolic 
evaluation and targeted ultrasound pattern. Given the paucity of data regarding this issue, it remains 
to be seen if different PCOS profiles will lead to different diagnostic and eventually more tailored 
therapeutic approaches. 
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TAB 3 DEMOGRAPHIC, ANTHROPOMETRIC AND HORMONAL CHARACTERISTICS, AND ULTRASOUND 
PATTERN FREQUENCY IN THE STUDY POPULATION STRATIFIED ACCORDING TO INSULIN 
RESISTANCE. 
Characteristics 
Group 1 
(n = 41) 
Group 2 
(n = 32) 
p value 
Age (years) 28.6 ± 6 28.5 ± 4.8 0.93 
BMI (kg/m
2
) 34.5 ± 5.9 23.5 ± 2.5 0.0001 
WHR 0.9 ± 0.5 0.8 ± 0.8 0.0001 
HOMA 5.1 ± 2.9 1.5 ± 0.6 0.0001 
Type B ovary 36/41 (87.8%) 7/32 (21.8%) 0.0001 
Type A ovary 5/41 (12.1%) 25/32 (78.1%) 0.0001 
Ovarian volume (cm
3
) 14.6 ± 5.6 11.9 ± 4.1 0.024 
SHBG (nmol/l) 27.2 ± 11.3 52.2 ± 21.1 0.0001 
Ferriman-Gallwey score 10.7 ± 3.3 11.3 ± 3.2 0.47 
Free testosterone (pg/ml) 2.5 ± 2.6 1.9 ± 1.5 0.36 
DHEA-S (µg/dl) 282.1 ± 391.1 252.5 ± 304 0.74 
17-OH-P (ng/ml) 1.2 ± 0.9 1.9 ± 1.7 0.93 
Results reported as means ± SD or percentage (%) 
BMI, body mass index; WHR, waist-height ratio; HOMA, homeostasis model 
assessment; SHBG, Sex hormone binding globulin; 17-OH-P, 17-hydroxy 
progesterone. 
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TAB 4 DEMOGRAPHIC, ANTHROPOMETRIC AND HORMONAL CHARACTERISTICS OF PATIENTS 
DIVIDED ACCORDING TO THE ULTRASOUND PATTERN OF PCOS. 
Characteristics 
Type A ovary 
(n = 33) 
Type B ovary 
(n = 45) 
p value 
Age (years) 28.4 ± 5.4 29 ± 5.8 0.61 
BMI (kg/m
2
) 23.7 ± 2.3 43.1 ± 56 0.048 
WHR 0.9 ± 0.1 0.9 ± 0.1 0.0001 
HOMA 1.5 ± 0.8 4.9 ± 2.8 0.0001 
LH (UI/L) 9.25 ± 6.3 5.2 ± 3.3 0.002 
Ovary volume(cm
3
) 12.1 ± 4 14.3 ± 5.6 0.048 
SHBG (nmol/l) 53.5 ± 23.5 28 ± 11.6 0.0001 
Ferriman-Gallwey 11.6 ± 2.9 10.5 ± 3.4 0.14 
Free testosterone (pg/ml) 2.6 ± 2.6 2.1 ± 1.7 0.27 
DHEA-S (µg/dl) 224.7 ± 221.7 164.4 ± 109.2 0.14 
17-OH-P (ng/ml) 1.8 ± 1.5 1.2 ± 1.3 0.057 
Results are reported as means ± SD  
BMI, body mass index; WHR, waist-height ratio; HOMA, homeostasis model 
assessment; PCOM, polycystic ovarian morphology; SHBG, Sex hormone binding 
globulin; 17-OH-P, 17-hydroxy progesterone. 
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Fig.2 Flow chart of patients enrolled in the study Standards for Reporting Diagnostic Accuracy (STARD). 
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Fig.3 Example of median ovarian section with the ovarian and stromal total areas defined.  Calipers are positioned so as 
to encircle the total gonad circumference (A1) and the stromal component circumference (A2). The stroma/total area 
(S/A) was also calculated. 
 
 
Fig.4 Sonographic pattern of a type A ovary (A). Note the typical rosary arrangement of follicles and the easily 
recognizable hyperechogenicity that results from thickening of theca (B). The stromal hypervascularity is clearly visible 
in C. Secondary aspects are the dominance of follicles with a diameter > 4 mm and the predominance of longitudinal 
diameter (D). 
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Fig.5 Sonographic pattern of a type B ovary (A). Note the ubiquitous arrangement of follicles, and the absence of 
central echogenicity (B). Characteristic signs of the type B ovary are a more "globular" gonad versus a type A ovary 
(C), with attenuation of the typical dominance of longitudinal diameter, and the presence of follicles with a mean 
diameter lower than those observed in Type A (D). 
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Chapter II: The role of environmental factors: The Endometriosis 
model 
 
1.   Endometriosis 
Endometriosis is considered one of the most frequent disease affecting the 6-10 % of women of 
reproductive age (2010). 
It is characterized by the presence of endometrial-like tissue outside the uterus able to provoke a 
chronic inflammation of the pelvis. In rare circumstances, endometriosis could also involve 
extrapelvic organs. Clinical manifestations are very variable among patients and consist in 
dysmenorrhea, infertility, chronic pelvic pain, dyspareunia bowel and or urinary disorders when 
these organs are also involved. 
 
1.a  Etiology and pathogenesis  
Several pathogenetic hypotheses have been advocated such as retrograde menstruation, lymphatic 
transport and coelomic metaplasiam, however the exact etiology still remains unknown (Sasson and 
Taylor, 2008), this is the reason why endometriosis is defined the “theories disease". 
Metastatic theory or retrograde menstruation 
Samson (1927) was the first to suggest that the menstrual bleeding, containing fragments of 
endometrium, moves through the fallopian tubes in a retrograde way and then settles into the 
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peritoneal cavity. In order to verify this theory experimentally, endometriosis was induced by 
insertion of menstrual flow or endometrial tissue into the peritoneal cavity in rhesus monkeys. It has 
been reported that abnormalities of the genital tract and consequent construction of the leakage flow 
cause endometriosis in teenagers. The prevalence of retrograde menstrual bleeding was diagnosed 
in 90% of women laparoscopically, thus it was considered a physiological phenomenon. The fact 
that only 25% of women develops endometriosis suggests that retrograde menstruation is only the 
premise but not the cause of the disease. Besides this theory does not explain all the localizations of 
endometriosis such as the most distinct ones as the mediastinum and pleura.  
Celomic metaplasia 
Postulated by Meyer (1919), this theory held that endometriosis arises from original celomica 
membrane by a process of metaplasia as a result of prolonged irritation and/or estrogenic 
stimulation. A correlation between short cycles and stage of the disease was found. Celomic 
epithelium gives origin to the ovarian epithelial cells, to the Müllerian duct and  to the peritoneal 
and pleural epithelium. Therefore, the mechanisms of this theory explain the presence of 
endometriosis in almost all the anatomical sites, including chest rectum and vaginal septum. 
 
Dissemination lymphatic and vascular 
Halban (1924) stated that endometrial cells once penetrated into lymphatic and blood vessels are 
responsible for an embolization process, often in ectopic sites. Although this mechanism can not be 
regarded as a common way of dissemination, however, it could be responsible for some rare 
extrapelvic localizations. 
 
Hormonal milieu 
 It was suggested the hypothesis that endometriosis can depend on the presence of circulating 
steroid hormones. Receptors for estrogen, progesterone and androgens have been found in 
endometriosic deposits. The latter seems to be positively influenced by estrogen, while it undergoes 
atrophy when exposed to androgen stimulation. 
 
Immune system 
The relationship between endometriosis and immune response had been reported for the first time 
by Weed & Arquenborg in 1980. It 's plausible that the endometriosic disease is a consequence of 
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alterations in the immune system that promote the establishment of lesions in the peritoneal cavity 
after the retrograde menstruation process (Alviggi et al, 2009; Alviggi et al.; La Cava et al.; 
Matarese et al., 2003; De Placido et al., 2001; Matarese et al., 2000; De Placido et al., 1998; De 
Placido et al., 1994). Immunological studies have shown reduced activity of natural killer cells in 
women with endometriosis. Other studies showed an increased concentration of white blood cells 
(macrophages, natural killer cells and T lymphocytes) in the peritoneal fluid of women with 
endometriosis. The increased secretion of growth factors and cytokines suggests that the presence of 
endometriosis induces a local intrapelvic inflammatory reaction. 
Independently of the different theories, the peritoneal environment seems to play an important role 
in pathogenesis. Molecular adhesion of cells and other factors produced by macrophages are 
responsible for the adhesion of fragments of endometrial tissue on the peritoneum. Later in the 
accession process, the growth of the endometrial tissue is favored and accelerated by steroid 
hormones, growth factors and angiogenic factors present in the peritoneal fluid. 
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2. The role of environmental pollutant in the pathogenesis of endometriosis: a 
systematic review of literature.  
 
2.a  Scientific background 
The possible involvement of toxicants in the pathogenesis of endometriosis was proposed for the 
first time by Rier and collaborators in 1993. In detail, they observed a dramatically increase of 
severe endometriosis among rhesus monkeys colony exposed to 2,3,7,8 tetrachlorodibenzo-p-dioxin 
(TCDD) (Rier et al., 1993). This report, published more than 20 years ago, led to large number of 
investigations regarding the possible impact of environmental pollutant on the pathogenesis of 
endometriosis. Apart from dioxin like compound and TCDD, several toxic agent have been 
associated with endometriosis such as phthalic acids, non dioxin like polychlorinated biphenyls 
(PCB), bisphenol (BP), trace elements, heavy metals, perfluorochemicals (PFC), particulate matter 
and pesticides.  
Fig.1 Adapted from Matarese et al. 2003. 
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Most of the published studies are retrospective and performed in small study populations. As 
consequence, contradictory results have been reported. In addition, methods adopted to quantify the 
effect were quite heterogeneous among studies. Hence, a definite conclusion about what kind of 
toxic agents are significantly associated with endometriosis was still not proposed. There are also 
scanty data about the underneath mechanisms by which environmental pollutants promote the 
growth of endometriosic lesions.  
A systematic review of literature was conducted with the aim to summarize all the available 
evidence regarding the relationship between environmental contaminants and endometriosis. 
  
2.b  Material and Method 
Systematic research and strategy 
A systematic research of the literature was performed with no time restriction.  Only clinical trials 
and reviews involving human have been selected. Only paper in English, Italian, French and 
German was included. 
Electronic searches were undertaken in the PUBMED, SCOPUS using the following keyword and 
search strategy: dioxins AND endometriosis; TCDD and endometriosis; PCB and endometriosis; 
dioxin like chemicals AND endometriosis; tetrachlorodibenzodioxin AND endometriosis; 
polychlorinated biphenyls AND endometriosis; phthalic acids AND endometriosis; phthalates AND 
endometriosis; cadmium and endometriosis; "Lead"[Mesh] AND endometriosis (PUBMED) OR 
“Lead” [Keyword] AND endometriosis (SCOPUS); heavy metals AND endometriosis;  trace 
elements AND endometriosis; arsenic AND endometriosis; chromium AND endometriosis; mercury 
AND endometriosis;  hydrocarbons, chlorinated AND endometriosis; toxic actions AND 
endometriosis;  pesticides AND endometriosis;  organochlorines pesticides and endometriosis; air 
pollutants AND endometriosis; air pollution AND endometriosis; particulate matter exposure AND 
endometriosis,   particulate matter AND endometriosis; benzene AND endometriosis; waste 
management pollutants AND endometriosis; waste disposal facilities AND endometriosis; landfill 
AND endometriosis; waste management AND endometriosis;  incineration AND endometriosis; 
incinerator AND endometriosis; 
Moreover we hand-searched in the reference of selected journal article found through database 
search including article in press. All review selected was deeply analysed to detected every possible 
paper overlooked.   
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Inclusion and exclusion criteria 
Inclusion criteria were all article and review regarding the association between endometriosis and 
environmental pollutants. Only peer reviewed articles were included. Only studies where the 
pollutant levels were directly measured in women have been included.  
Exclusion criteria included: in vitro studies; Case report or case series; unpublished data; Study 
involving animals; the use of not conservative statistic method (Bayesian analysis). Studies with 
overlap between cases and controlled have also been excluded:  
 
Data extraction 
Studies and reviews were screened by 4 reviewers (A.C., R.B., C.B., F.D.) independently and any 
disagreement was solved by discussion. Firstly, all titles and abstracts from the databases were 
examined, but only those with the possibility of meeting the predefined criteria were kept for further 
evaluation. Final inclusion decisions were made on examination of the full manuscript. Hand 
searches of reference lists of literature review and in press article have been used to complement 
computer search.  
 
Quality assessment 
Newcastle Ottawa scoring system was adopted for the quality assessment of each study (Eliyahu et 
al., 2016). Newcastle Ottawa scale allocates a maximum of 9 scores for case control and cohort 
studies and a maximum of 10 scores for cross-sectional study.  
Specifically, each paper was independently evaluated by two authors (A.C and B.F) and final 
decision was reach after full discussion between authors. The following items were evaluated: 
 Selection, comparability and exposure for case-control studies. 
 Selection, comparability and outcome for cohort study and cross-sectional study. 
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2.c  Results 
Dioxin-like compounds  
Belonging to the family of polyhalogenated aromatic hydrocarbons (PHAHs), dioxins-like 
compounds are a class of 210 organochlorines, divided into 75 polychlorinated dibenzo-p-dioxins 
(PCDDs) and 135 polychlorinated dibenzofurans PCDFs. On the other hand, PCBs dioxin like 
(PCB 77, 81, 105, 114, 118, 123, 126, 156, 157, 167, 169, 189) compounds also known as coplanar 
or non-ortho PCB, are twelve toxicants which show the same “dioxine-like” properties but could 
not be defined as dioxins (USA Enviromental Protection Agencies). Among all dioxin products, 
2,3,7,8 tetrachlorodibenzo-p-dioxin (TCDD) have demonstrated the most relevant toxic effect.  
Dioxins are generally contaminants produced during industrial activities or waste incineration of 
chlorinated organic compounds. In addition, some amounts of dioxins are also produced during 
cigarettes smoking and steel manufactured process. Dioxins can also be generated by natural events, 
such as volcanic eruptions and forest fires. The most important exposure for humans mainly occurs 
by consumption of contaminated food (WHO, 2012) (WHO 2002).  
Concentrations of dioxins are expressed as toxic equivalent factor (TEF) per g of lipids considering 
that adipose tissue constitute the main compartment store.  
The majority of toxic activity for dioxin and dioxin like compounds is mediated by a specific 
receptor aryl hydrocarbon receptor (AhR) (Bruner-Tran and Osteen, 2010). The AhR is a ligand 
activated transcription factor which is present in cytosol as a complex associated with specific 
chaperone protein. When activated AhR is able to influence gene expression in the nucleus 
interacting with the aryl hydrocarbon nuclear translocator. The AhR is commonly expressed in the 
endometrium (Bruner-Tran and Osteen, 2010, Igarashi et al., 1999, Bulun et al., 2000) and in 
reproductive female tissue. It was also supposed to have relevant role in ovarian reserve 
(Richardson et al., 2014). AhR modulates metalloproteinases synthesis which is involved in 
endometriosis development (Tosti et al., 2015) and the usual resistance of ectopic endometrial cells 
to progesterone (Bruner-Tran et al., 1999). 
Moreover, a strict interaction between estrogen receptor (ER) and AhR had been widely 
demonstrated (Richardson et al., 2014, Bruner-Tran and Osteen, 2010), supporting the fact that 
dioxin pollutant could significantly influence the function of estrogens and progesterone targets.  
An effect mediated by RANSES pathway was also demonstrated   
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Finally, dioxins compounds are also able to interfere with immune-endocrine system of the 
endometrium enhanced the sensitivity to proinflammatory factors (Bruner-Tran et al., 2008).   
A total of 20 studies has been included, 12 about dioxins and 8 about DLPCBs. Differences were 
found regarding the diagnostic method, type of pollutant analysed, type of controls, and method 
adopted for the assessment of the contaminants.  
According to ESHRE guidelines, the gold standard diagnostic method consist in laparoscopic (or 
surgical) visualization and histological confirmation of endometriosic lesions, however the sole 
laparoscopy have a high negative predictive value (Dunselman et al., 2014). In the most of papers 
included (n = 18) endometriosis was assessed by laparoscopy and among these, in 9 out of 20, the 
diagnosis was confirmed by histology. A questionnaire was used by Fierens et al. In population 
study investigated by Eskenazi et al. 14 out of 19 cases was defined by laparoscopy or surgery.  
Regarding controls selection, most of authors included patients where endometriosis had been 
excluded by laparoscopy. In Niskar et al. study (2009), only 30 out of 64 controls was determined 
by laparoscopy. On the other hand, Heiler et al (2004 and 2005) considered did not as control only 
patients with no clinical or ultrasound signs of endometriosis without laparoscopic or histologic 
confirmation.    
In the most of papers dioxin compounds have been analysed with discordant results and diverse 
analytic methods. Dioxin compounds were measured in 12 studies (Mayani et al., 1997, Cai et al., 
2011, De Felip et al., 2004, Eskenazi et al., 2002, Fierens et al., 2003, Heilier et al., 2005, 
Martinez-Zamora et al., 2015, Niskar et al., 2009, Pauwels et al., 2001, Porpora et al., 2009, Simsa 
et al., 2010, Tsuchiya et al., 2007) 
Chemically activated luciferase expression bioassay (CALUX) assay was adopted in three studies 
(Pauwels et al., 2001, Porpora et al., 2009, Simsa et al., 2010) while in nine study a combination of 
gas chromatography and mass spectrometry was adopted for the measurement (Cai et al., 2011, De 
Felip et al., 2004, Eskenazi et al., 2002, Fierens et al., 2003, Heilier et al., 2005, Martinez-Zamora 
et al., 2015, Mayani et al., 1997, Niskar et al., 2009, Tsuchiya et al., 2007).  
Results as well as type of pollutant analysed were also different among studies.  
Regarding dioxin compounds the most of the studies did not found any significant association 
(Porpora et al., 2009, De Felip et al., 2004, Eskenazi et al., 2002, Fierens et al., 2003, Niskar et al., 
2009, Pauwels et al., 2001, Tsuchiya et al., 2007) while five trials detected a possible significantly 
interaction (Cai et al., 2011, Heilier et al., 2005, Martinez-Zamora et al., 2015, Mayani et al., 1997, 
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Simsa et al., 2010) . Specifically, both Heiler et al. in 2005 and Martinez Zamora et al. in 2014 
founded a significant association with deep infiltrating endometriosis (Heilier et al., 2005, 
Martinez-Zamora et al., 2015).  
In detail, Heiler et al. 2005 found a significantly increase of deep endometriosic nodules for an 
increment of 10 pg in total TEQ levels/g lipids of dioxin compounds (OR: 3.3; CI  95%, 1.4 –7.6) 
(Heilier et al., 2005). Recently, Martinez Zamora et al. compare dioxin like PCBs congeners levels 
in omentum of patients affected by deep pelvic endometriosis with control without endometriosis. 
Toxic equivalence and concentration including all the pollutant analysed was found significantly 
higher in the omentum of the first group. Among all dioxins like PCBs analysed only PCB 114, 
189, 126, 159 were statistically higher in DIE patients (Martinez-Zamora et al., 2015) 
Cai et al. (2011) is the only study where dioxins levels were measured in peritoneal fluid. The 
authors founded higher concentration of PCDFs and DLPCBs in peritoneal fluid of women with 
endometriosis comparing with serum levels. Of interest, serum concentration of dioxin compounds 
was similar between case and controls. Finally, statistical results indicate that higher concentration 
of dioxin compounds in peritoneal fluid were associated with increased risk of endometriosis (OR 
2.5 CI 95% 1.17-5.34; p = 0.035) (Cai et al., 2011). 
Despite Porpora and Pauwels finding (Pauwels et al., 2001, Porpora et al., 2009) adopting the same 
method, Simsa et al. (2010) detected an increased risk to develop endometriosis among patients 
with high serum levels dioxin compound (≥ 25 pg TEQ/g lip) compared with lower level (≤14 og 
TEQ/g lip) (OR 2.44 CI 95% 1.4-5.70) .  
Mayani et al. (1997) and Eskenazi (2002) focused their attention only on the TCDD, who showed 
the most toxic properties among dioxin compounds. Specifically Mayani et al.  (1997) designed the 
first case control where both cases and controls were ascertained with laparoscopy. Although a 
significant number of women positive for dioxin in serum was detected in endometriosis group 
(8/44 18% vs 1/35 3% p = 0.04) the OR did not reach statistical significance (OR: 7.6 CI 95% 0.91-
169.7). 
On the other hand Eskenazi et al. (2002) conducted large cohort trial in Seveso population almost 
20 years later factory explosion in 1976 which resulted in elevated dispersion of dioxins compounds 
among rural population (Eskenazi et al., 2002). Population study was composed by 19 cases (14 
surgical confirmed) and 277 controls (only 39 surgical confirmed). The authors observed a doubled 
but no significant relative risk ratio for women with higher TCDD levels >100ppt compared with 
patients with lower TCDD levels ≤20ppt (RR 2.1 CI 90% 0.5-8.0).   
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Polychlorinated biphenyls 
Polychlorinated biphenyls were introduced in 1930 and are commonly used for their electrical 
insulating properties as s dielectric fluids in transformers, capacitors and coolants. Belonging to the 
family of chlorinated hydrocarbons, these compounds are characterized by 1-10 chlorine atoms 
linked to a biphenyl in turn composed by the connection of two benzene rings by a carbon carbon 
bond (Bruner-Tran and Osteen, 2010). 209 congeners have been identified. The toxicity of these 
pollutants is strictly related to the number of chlorines.  
Although their production was banned in 1976 these toxicants are still present in our environment 
including water and food. In addition there is evidence that exposure to PCBs could be associated 
with tumors like malignant melanoma, hepatocellular carcinoma and non Hodking lymphoma 
(Lauby-Secretan et al., 2015). All PCBs were classified as carcinogenic for humans, however the 
evidence is still considered inadequate in the human for toxicants with dioxin-like properties 
(Lauby-Secretan et al., 2015).  
While dioxin-like PCBs exert their toxic effect through AhR, the role of non-dioxin like PCBs is 
still unclear. Some authors have reported a significant influence on the growth of endometrial cells 
to high exposure to PCBs (Johnson et al., 1997). Others have also postulated their interaction on 
pro-inflammatory activity and pro-metastatic factors (Sipka et al., 2008). 
Furthermore, an antiestrogenic or estrogenic activity has been hypothesized among PCBs. One of 
the first characterization of estrogen activities of PCBs was proposed by Cooke in 2001 (Cooke PS, 
2001) and used by Buck Louis et al. in 2005. Nonetheless, recent evidences are not consistent with 
these results (Table 2).  
Among 21 studies which have investigated the role PCBs in the endometriosis, 17 studies focused 
about the possible role of NDL-PCBs congeners. The most investigated non dioxin like congeners 
were 138-153-180 (Table 1).  
As for paper regarding dioxins compounds a relevant heterogeneity among studies was found.  
In the most of paper selected endometriosis was assessed by laparoscopy (n = 18) and among these 
9 with histological diagnosis. Only two studies adopted questionnaires to address endometriosis 
diagnosis.  
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Among all 209 congeners, only 45 PCBs congeners have been analysed (Table 3). Comparable 
levels of PCBs 18, 28, 44, 49, 66, 74, 77, 81, 87, 99, 123, 128, 146, 149, 151, 157, 169, 172,177, 
178, 183, 187, 194, 195, 196, 201, 206, 209 was found both in patients and in controls.  
On the other hand a significantly higher level in patients affected by endometriosis was found for 
seven DL PCBs congeners 105, 114, 118, 126, 156, 167,189 and eleven NDL PCBs congeners 1, 5, 
29, 52, 98, 101, 138, 153, 156, 170, 180. (Martinez-Zamora et al., 2015, Porpora et al., 2006, 
Porpora et al., 2009, Quaranta et al., 2006, Roya et al., 2009, Vichi et al., 2012, Gerhard and 
Runnebaum, 1992).  
Specifically Quaranta et al (2006), Porpora et al. (2006), Porpora et al. (2009) and Vichi (2012) 
showed the same population study. Among these, the largest one (Porpora et al., 2009) reported a 
significant odds ratio for DL-PCB-118 OR = 3.79; 95% CI 1.61–8.91), NDL-PCB-138 (OR = 3.78; 
95% CI, 1.60–8.94), NDL-PCB-153 (OR = 4.88; 95% CI, 2.01–11.0), NDL-PCB-170 (OR = 3.52; 
95% CI, 1.41–8.79), NDL-PCB 180 OR 3.05 95% CI 1.25–7.42). The same results were no 
observed by the other authors with no significant odds ratio reported (Trabert et al., 2010; Niskar et 
al., 2009; Tsuchiya et al., 2007).  
In a large matched cohort study, Buck Louis (2012) assesses the role of PCBs in two cohorts. The 
former constituted by women where the diagnosis of endometriosis was performed surgically 
(operative cohort), the latter where the endometriosis was diagnosed by MRI imaging (population 
cohort). All PCBs was measured both in serum and fat tissue in operative cohorts and only in serum 
in population cohort. Specifically, Buck Louis did no confirmed Porpora group findings both in 
population and operative cohorts: PCB 118 (Operative ORa 1.01 95% CI 0.83, 1.24; Population ORa 
1.06 95% CI 0.66, 1.71); PCB 138 (Operative ORa 0.98 95% CI 0.80, 1.20 Population ORa 0.80 
95% CI 0.40, 1.63); PCB 153 Operative ORa 0.87 95% CI 0.71, 1.07 Population ORa 1.13 95% CI 
0.68, 1.89; PCB 170 (Operative ORa 0.79 95% CI 0.62 1.02 Population ORa 0.72 95% CI 0.32, 
1.62); PCB 180 (Operative ORa 0.91 95% CI 0.74, 1.12 Population ORa 0.77 95% CI 0.40, 1.50) 
(Buck Louis et al., 2012). A reduced odds of endometriosis was reported for PCB 74 (ORa 0.72 
95% CI 0.55-0.93) and PCB 156 (ORa  0.74 95% CI 0.57 0.96). All odds was adjusted for age, 
parity BMI, breastfeeding, serum cotinine levels and serum lipids. When breastfeeding an parity 
was removed and increased odds of endometriosis was observed for PCB 151 (ORa 3.23 95% CI 
1.43-7.28).   
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Although several study showed higher levels of PCBs 1, 5, 29, 98, 128, 153,180 among patients 
with endometriosis no odds ratio was reported (Roya et al., 2009, Gerhard and Runnebaum, 1992, 
Reddy et al., 2006).  
Of interest a possible association between PCBs and deep endometriosis was reported in a small 
size case control study. In detail several NDLPCBs (3, 8, 28, 52, 101, 153, 180, 194, 206, 209) and 
one DLPCB (118) have been assessed in serum of women with laparoscopic diagnosis of 
endometriosis and histologic diagnosis of adenomyosis. Comparing with controls, patients with 
adenomyosis showed higher levels of all PCBs analysed but no odds ratio was reported (Heilier et 
al., 2004). 
In literature, there are scanty data regarding the relationship between NDL-PCBs congeners and 
deep endometriosis. Only one study form Heiler et al. in 2004 found an increased levels of total 
PCBs which include 10 NDL-PCBs congeners (3, 8, 28, 52, 101, 153, 180, 194, 206, and 209) and 
only one DL-PCBs congener (118) in patients with deep pelvic endometriosis (Heilier et al., 2004). 
The weight of the single NDL congeners was no reported by the authors.  
 
Trace elements 
Trace elements have long been studied in gynecology because of their interference with the 
endocrine system. The environmental presence of some of these, in particular cadmium, lead and 
mercury has been associated to the industrial activity and the presence of non-physiological 
detectable levels of these non-essential elements in the blood of most adults is to be considered a 
result of years of industrial activity and pollution. Adsorption of these substances is through the 
respiratory tract (inhalation) or through the digestive tract (ingestion of food, mainly fish and 
contaminated water). Through the bloodstream they reach various organs and systems with different 
mechanisms of action (Bridges and Zalups, 2005). Hormonal effects of these metals has been 
widely demonstrated by years of experience, until the identification of a specific group of emerging 
inorganic xenoestrogens, appropriately called metalloestrogens (Darbre, 2006). In particular lead 
and mercury, as bivalent metals, are capable to binding to the estrogen receptor (Zhang et al., 
2008), by interfering with estrogenic activity and are thought to have antiestrogenic effects (Young 
et al., 1977; Martin, 2003); on the other hand cadmium has been shown to activate estrogen 
(ERalpha) and androgen receptor and inhibit the binding of Estradiol to ERalfa (Young et al., 1977, 
Stoica et al., 2000, Brama et al., 2007). Effects on female reproductive system are different, 
epidemiological studies have shown antiestrogenic effects of lead and estrogenic effects for 
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cadmium (Brama et al., 2007, Jackson et al., 2008, Silva et al., 2012) but is not still clear their role 
in several endocrine diseases. 
To date few studies have evaluated relationship between this class of metalloestrogen and estrigenic 
diseases like endometriosis. Our analysis led us to the selection of four case-control studies (Heilier 
et al., 2004, Heilier et al., 2006, Silva et al., 2013, Turgut et al., 2013, Itoh et al., 2008) and one 
cohort study (Pollack et al., 2013). Among these we have excluded the study of Itoh (2008), since 
the control group included women with endometriosis stage I and II, which may be a confounding 
factor (Itoh et al., 2008).  
The two studies of Heilier (2004, 2006)  have not showed a role of cadmium in the pathogenesis of 
endometriosis, despite its demonstrated estrogenic activity, but showed significant lower levels of 
lead in the group with endometriosis. But it must emphasize that the two study groups did not differ 
in terms of age and smoking, but one of them (Heilier et al., 2006) differ in BMI; this may affect 
the proportion of endogenous estrogenic activity in the two groups. Moreover in both experiences 
while the diagnosis of endometriosis it was made through laparoscopy and histological 
confirmation, in the control group the presence of asymptomatic endometriosis cannot be excluded 
at all, not subjecting patients to laparoscopic examination.  
In their experience, Silva et al. (2013) have demonstrated for the first time elevated blood levels of 
nickel in women with endometriosis, but this is an isolated result and would require further 
confirmation. In the same study group there were no different levels of lead and cadmium (Silva et 
al., 2013).  
Turgut in 2013 found high levels of cooper in women with endometriosis compared to controls, but 
in the selection of patients has included among the cases of endometriosis only the advanced stages 
(III and IV). Also little is known about the possible role as endocrine disrupter of copper and for 
these reasons we cannot consider this result a clear link between exposure to copper and the 
development and progression of the disease (Turgut et al., 2013). The only cohort study (Pollack et 
al., 2013) does not clarify the relationship between cadmium, lead, mercury, arsenic, chromium and 
the pathogenesis of endometriosis, obtaining conflicting results in the different cohorts.  
 
Phtalates compound and endometriosis 
Phthalates compounds are widely used in plastic industries and added in considerably amounts to 
cosmetics and are considered as ubiquitous contaminants (Wittassek et al., 2011). Biochemically, 
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these compounds are characterized by alkyl diesters of phthalic acid which are rapidly metabolized 
and eliminated by urine in form of mono esters. For this reason urine analysis is considered a 
reliable tool to test phthalates exposure (Wittassek et al., 2011). 
Considering the wide used of cosmetics among women, the exposure was estimated dramatically 
high in this population compared with men (Wittassek et al., 2011). In addition, phthalates 
compounds could be present in several medications such as didanosine, omeprazole and 
theophylline. As a matter of fact, in subjects taking these medications, a significantly higher levels 
of phthalates metabolites were observed (Hernandez-Diaz et al., 2009).  
With respect of female reproductive activities, an involvement of phthalates in alteration of 
menstrual cycle and polycystic ovarian syndrome was suggested (Davis et al., 1994). In addition, an 
effect of phthalates products on reproduction was assessed in animal models (Agarwal et al., 1985, 
Agarwal et al., 1989). In vivo study demonstrated how some phthalates such as DEHP and DnBP 
could interact to estrogens receptors ESR 1 (Takeuchi et al., 2005).  
The role of phthalates compounds in the pathogenesis of endometriosis were investigated. A total of 
nine studies have been identified in literature. In detail, an increased plasma levels of di-2 
ethylhexyl phthalates (DEHP) was detected in 2003 in 35 endometriotic patients in a case control 
study (0.57 ug/ml versus 0.18 ug/ml; p = 0.0047) (Cobellis et al., 2003). Subsequently, a series of 
studies focused the role of phthalates compounds in the development of endometriosis in Indian 
population (Heilier et al., 2005, Reddy et al., 2006a, Reddy et al., 2006b, Rozati et al., 2008). 
Higher phthalates compounds levels concentrations were found in Indian patients affected by 
endometriosis with a progressively increasing in advanced stages. Huang et al. found higher levels 
of MnBP metabolites in the urine of women affected by endometriosis compared with control group 
On the other hand, of seven urinary phthalates metabolites analysed (MMP, MEP, MnBP MBzP, 
MEHP, 5oxo-MEHP and 5OH-MEHP) no difference was seen in patient with adenomyosis (Huang 
et al., 2010). 
Comparing the highest versus the lower of MBP and MEHP a large cross sectional study found a 
significant risk to develop both leiomyomatosis and endometriosis for urinary metabolites MBP 
(OR 1.71 CI 95% 1.07-2.75), but a weak inverse association for MEHP (OR 0.59 CI 95% 0.37 -
0.95) (Weuve et al., 2010). Nonetheless, both condition was self-reported by the patient with no 
surgical confirmation In addition, when analysed alone no association found between all 
metabolites analysed and endometriosis. On contrary, elevated MEHP plasma levels in patients with 
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endometriosis was found by Kim et al. in 2011 in a case-control study of 266 women (97 cases and 
169 controls) (OR 1.020 CI 95% 1.003–1.038; p = 0.020) (Kim et al., 2011).  
In 2013, Upson described for the first time an inverse relationship between endometriosis and 
MEHP urinary concentrations (adjusted OR 0.3 CI 95% 0.1, 0.7 p = 0.012). The same authors 
detected a inverse no significant association with DEHP metabolites (5 OH MEHP and 5oxo 
MEHP). On the other hand their data showed and increased but no significant endometriosis risk 
with greater urinary concentrations of MBzP and MEP (Upson et al., 2013b).  
On the other hand Buck Louis in the same years in a large cohort study described a 1.7 fold or 
higher odds of endometriosis for four phthalates compounds MECPP MEHP, 5 OH MEHP, 5oxo 
MEHP. When OR was adjusted for age creatinine and BMI also mBP and mCMHP resulted 
significantly associated with endometriosis. However, these findings was observed only in 
population cohort where endometriosis was diagnosed by magnetic resonance (MRI) (Buck Louis et 
al., 2013) Finally, the last study published in 2014 showed a only marginally increased levels of 
MEHP in patients affected by endometriosis or adenomyosis.  
 
Bisphenols 
The bisphenols are a group of chemical compounds with two hydroxyphenyl functionalities derived 
from the synthesis of plastics materials and some additives. "Bisphenol" is a common name, the 
letter following refers to one of the reactants. Bisphenol A (acetone) is the most popular 
representative of this group, often simply called "bisphenol”. Bisphenols are endocrine disruptors 
and they have been characterized as a "pseudo-persistent" chemical leading to its spreading and 
potential accumulation in a variety of environmental matrices as the adipose tissue, giving rise to 
persistent, although low, serum levels (Yang et al Environ Health Perspect. 2011). Therefore, highly 
sensitive and selective analytical methods are needed for determination of low levels of BPA and 
BPB in serum samples. BPA shows estrogenic activity towards cell lines and endocrine-disrupting 
effects in vivo (Rier and Foster, 2002; Zeyneloglu et al., 1997; Cobellis et al., 2003; Ashby et al., 
1998; Ashby and Odum, 2004; Bergeron et al., 1999; Kim et al., 2002; Matthews et al., 2001). The 
interaction of BPA and/or BPB with estrogenic receptor produces the activation of the same 
transcriptional-factor (CREB) as 17-β-estradiol (Tinwell et al., 2000; Quesada et al., 2002). 
Furthermore, previous studies have shown a relationship between BPA (and its metabolites) serum 
concentration increase and altered secretion of gonadotropic hormones and increase of androgenic 
hormones (Takeuchi et al., 2004, 2006). Probably, this mechanism determines a greater production 
45 
 
of estrogens, favoring the proliferative and inflammatory characteristics of endometriosis. The role 
of bisphenols compounds in the pathogenesis of endometriosis have been investigated. In our 
review a total of three studies have been included from literature. In one case-control study 
(Cobellis et al., 2009) the analyses of sera from both healthy  and endometriotic women emphasized 
the absence of bisphenols in all the control cases (11 women), whereas BPA was found in 30 sera 
(51.7%) and BPB was found in 16 sera (27.6%) in the group of 58 patients with endometriosis; in 
nine of such sera BPA and BPB were present simultaneously. At least one of the bisphenols was 
found in 63.8% of sera of 58 patients with endometriosis. These findings strongly suggest the 
existence of a relationship between occurrence of endometriosis and the presence of BPA and/or 
BPB in the serum. One limitation of this study was the absence of multivariable analysis to adjust 
for potential confounders. In a matched cohort design “The ENDO Study”  (M. Buck Louis et al. 
2013) ,the aim was to assess the relation between persistent environment chemicals (phtalates and 
bisphenol a) and endometriosis by the hand of an operative and population cohort. The operative 
cohort comprised 495 women undergoing laparoscopy/laparotomy, while the population cohort 
comprised 131 women matched on age and residence. Surgically visualized or pelvic magnetic 
resonance imaging (MRI) diagnosed endometriosis in the two cohorts, respectively. The relation 
between BPA and endometriosis was evident in the population cohort (not in the operative one ) 
and only emerged as significant when adjusting for parity along with other relevant covariates 
(AOR=1.97; 95% CI 1.04, 3.72). If endometriosis and parity share a common origin, its adjustment 
may induce over adjustment bias yielding a spurious finding. One study limitation includes the 
inability to detect endometriosis stages 1–2 in the population cohort, given the limited sensitivity 
and specificity of MRI for detecting milder disease relative to histologically confirmed disease. 
Despite errors associated with MRI diagnosed endometriosis relative to the clinical gold standard of 
visualization, the blinding of surgeons and radiologists to women‟s chemical concentrations argues 
against biases. 
 
Organochlorine pesticides 
Organochlorine pesticides (OCPs) are widely used in the latter half of the 20th century. The OCPs 
are usually divided into three main groups including dichlorodiphenyltrichloroethane and its 
derivates (p,p´ DDT p,p´-DDE o,,p´ DDT), isomers of hexachlorocyclohexane (β- γ HCH) and 
chlorinated cyclodiene such as aldrin and dieldrin. OCPs showed estrogenic activity in vitro 
(Andersen et al., 2002) and in animal model were able to alter normal reproductive functions 
(Alvarez et al., 2000, Shelby et al., 1996). A damage to central nervous system, liver, kidney and 
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bladder, derived from long term exposure to OCPs, was also observed (Shaw, 1992). Humans could 
be exposed to these pesticides via several routes including breathing polluted air, dermal penetration 
but contaminated food represent the main source of human exposure (Hassall, 1990). Limited 
attention has focused on persistent organochlorine pesticides (OCPs) and their association with 
endometriosis, despite their sharing a similar chemical structure with dioxins and PCBs and their 
ubiquitous presence in the environment. In our review we include 5 studies which investigate the 
association between endometriosis and OCPs exposure. Preliminary, data from Lebel and Gerrard 
did not reported any increased incidence of endometriosis among patients exposed to OCPs (Lebel 
et al., 1998, Gerhard and Runnebaum, 1992).  
In one cohort study (Cooney et al. 2010), it has been found that OCPs were associated with an 
elevated adjusted odds of having a laparoscopically confirmed endometriosis diagnosis when OCP 
serum concentrations were in the highest tertiles for hexachlorobenzene (HCB) (aOR = 6.4; 95% 
CI, 1.0 - 42.8) compared with women in the lowest category .These associations persisted and were 
often stronger in the models when the concentrations of the chemicals were transformed and 
examined in a continuous fashion. The adjusted odds for endometriosis among women for a per unit 
log transformed increase in HCB was 1.4 (95% CI, 0.5, 3.9) and 5.0 (95% CI, 0.7 - 35.8) per unit 
log transformed increase in t-nonachlor. When OCP concentrations were left in their original unit 
but grouped by structure, significantly elevated aORs were observed for the highest tertile of 
aromatic fungicides (aOR = 5.3; 95% CI, 1.2 - 23.6) and elevated but not statistically significant 
aORs were observed for cyclodiene insecticides (aOR = 2.7; 95% CI, 0.8 - 9.5), as well as the 
midrange tertile for chlorinated insecticides (aOR = 1.6; 95% CI, 0.5 - 5.3). These findings all 
suggest an association between OCP exposure and endometriosis. Buck Louis (2012) in a large 
matched cohort study observed an significant association between endometriosis and HCH γ-β 
isomers respectively in operative (n = 473) and population cohort (n = 127) (γ HCH: adjusted OR = 
1.27; 95% CI: 1.01, 1.59; β HCH adjusted OR = 1.72; 95% CI: 1.09, 2.72). Operative cohort and 
population cohort was constituted by women where endometriosis was diagnosed with laparoscopy 
and magnetic resonance respectively (Buck Louis et al., 2012). 
In another population-based case-control study, OCPs were measured in serum of surgically 
confirmed endometriosis cases (n = 248) and from population-based controls (n = 538). An 
increased endometriosis risk associated with serum concentrations of β-HCH (third vs. lowest 
quartile: OR = 1.7; 95% CI: 1.0, 2.8; highest vs. lowest quartile OR = 1.3; 95% CI: 0.8, 2.4) and 
mirex (highest vs. lowest category: OR = 1.5; 95% CI: 1.0, 2.2). Interestingly, the association 
between serum β-HCH concentrations and endometriosis was stronger in patients with ovarian 
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endometriosis (third vs. lowest quartile: OR = 2.5; 95% CI: 1.5, 5.2; highest vs. lowest quartile: OR 
= 2.5; 95% CI: 1.1, 5.3) (Upson et al., 2013a). 
Perfluorochemicals 
Perflurochemicals are organofluorine compounds containing carbon and fluorine characterized by 
long half-life (2.5 to 7.3 years) with elevated blood concentration documented in populations 
exposed (Olsen et al., 2007, Karrman et al., 2006); These man-made chemicals are used in several 
industrial applications: textile industries, cleaning aids and surfactants (Karrman et al., 2006). 
Diverse routes of exposure were suggested such as air, water, food and household dust, however the 
main one was not definitely established (Karrman et al., 2006). 
Among persistent organic pollution only one study addressed the role of perflurochemicals on 
endometriosis. In population where endometriosis was diagnosed by endoscopic visualization 
serum perfluorooctanoic acid (PFOA) (OR = 1.89 CI 95% = 1.17–3.06) and perfluorononanoic acid 
(OR = 2.20 CI 95% 1.02–4.75) was associated with endometriosis. matching both operative and 
population cohorts, perfluorooctane sulfonic (PFOS) acid (1.86 [1.05–3.30]) and perfluorooctanoic 
acid (PFOA)(OR = 2.58 CI 95 1.18–5.64) seemed to increase the odds for moderate/severe 
endometriosis (OR = 1.50 and 1.86, respectively). These findings were moderately attenuated with 
parity adjusted (Louis et al., 2012).  
 
Air pollution and particulate matter  
Air pollution consist in exposure to several kind of molecules including traffic exhaust (diesel and 
no diesel) including microscopic solid or liquid matter suspended in the earth atmosphere also 
knows as particulate matter (PM). Sources of PM are essentially man-made but could also be 
natural (volcanoes, seismic activities). They have impacts on climate and precipitation that 
adversely affect human health. PM with a diameter of 10 micrometers or less, also known as PM10, 
that can be inhaled but cannot cross the alveolar district. On the other hand, PM with a diameter of 
2.5 micrometers or less, also known PM 2.5 can cross into the blood stream, deposit at distant 
tissues. Exposure to air pollution and PM is of great concerning in public health and were 
associated with increased mortality and hospitalization, especially for cardiovascular disease, stroke 
and lung disorders (Brook et al., 2010, Calderon-Garciduenas et al., 2011, Brook et al., 2004). 
Regarding the possible involvement in endometriosis pathogenesis, experiments in vivo have 
showed that in utero exposure to diesel exhaust could promote the persistence of endometriosis 
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lesion in rats (Umezawa et al., 2011). In addition there is evidence that exposure to air pollution 
may improve proinflammatory factors and oxidative (Brook et al., 2004, Brook et al., 2010) stress 
both involved in previous study in the development of endometriosis (Chen et al., 2010, Van 
Langendonckt et al., 2002).   
There are few study which have address the role of particulate matter and air pollution on 
endometriosis pathogenesis.  
We found one cohort study (Mahalingaiah et al., 2014) that evaluated the association of air 
pollution exposures during adulthood, including exposure to particulate matter (PM 2.5, PM 10-2.5, 
PM 10), and timing of exposure with risk of endometriosis in a cohort from the Nurses‟ Health 
Study II with 10 years of follow-up. Only women who reported a laparoscopic diagnosis of 
endometriosis after 1993 through 2007 were included. Exposure to pollutant was evaluated by the 
calculation of the distance between residential address of participants and nearest road. For the 
primary analysis, the distance was categorized in 0-50 meters, 50-199 meters and ≥200 meters. 
Predicted ambient exposure to particulate was available using a data from the U.S. Environmental 
Protection Agency (EPA, 2013) Air Quality System, a nationwide network of continuous and filter-
based monitors. The authors evaluated the hazard ratio of endometriosis by residential proximity to 
roadway and for each 10-μg/m3 increase in particulate matter. Finally, no significant ratio was 
reported for all PM analysed considering the exposure averaging time of 2 years, 4 years and 
cumulative. In addition, the authors found no significant hazard ratio to develop endometriosis with 
respect to distance to main roadway.  
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2.d  Discussion 
This line of research has pointed out the potential role of environmental pollutants in the 
pathogenesis of endometriosis. The neuro-ormonal control of the reproductive function is based on 
the connection of the hypothalamus-pituitary gland with the ovary, which in turn is crucial  in 
controlling the competence of endometrium. So, it could be concluded that the endometrium is part 
of a whole which has been defined as hypothalamus-pituitary-gonadal-endometrial axis. Even if the 
etiology of endometriosis is still uncertain, the pathogenesis has two main steps: the ectopic 
distribution of the endometrial tissue and its response to the hormonal stimuli. The environmental 
pollutants seem to act as strong endocrine disruptors, causing and strengthening both the 
mechanism at the base of endometriosis, breaking the physiological connection between the 
hypothalamus-pituitary axis and the endometrial tissue. Even if this behavior has been studied for 
all the contaminants, through different mechanism as explained in the results, only few significant 
associations have been demonstrated.  
Several studies supported the effect played by dioxins and PCBs on etiopathogenesis of 
endometriosis, so that it‟s possible to conclude that there is a moderate evidence of the relation 
between endometriosis and these pollutants. In detail, higher levels of polychlorinated dibenzo-p-
dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs) and PCBs (especially PCBs 138, 153, 
180) were observed in patients affected by endometriosis. There are also evidence that support a 
role of PCBs and dioxins in the pathogenesis of deep endometriosis and adenomyosis. Contrasting 
results were found regarding the association between phthalates and endometriosis. With respect of 
organochlorines pesticides, only β-hexachlorocyclohexane was associated with an increased odds of 
endometriosis. Only one study reported a significantly associations between perfluorochemicals 
[perfluorooctanoic acid (PFOA) and perfluorononanoic (PFNA)] and benzophenone metabolites 
[2,4-dihydroxybenzophenone (2OH BP)] with endometriosis. No association was found between 
endometriosis and trace elements, including cadmium, despite its demonstrated estrogenic activity. 
This can be explained by the presence of a endogen protect mechanism from the toxic effects of 
heavy metals, such the metallothionine (Klaassen CD, J Toxixol Sci, 1998; Waalker HP, Cancer 
Research, 2004). To date, a direct relation between trace elements and endometriosis cannot be 
demonstrated. 
This study has some limitations that couldn‟t be overcome and that could have interfered on the 
analysis. First, the measurement used to estimate the personal exposures is indirect as it is based on 
the ambient exposure and not always on blood analysis. Second there are no information on 
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workplace exposures or the proportion of days spent at home, or on domestic characteristics (e.g., 
age, ventilation rate, air purification systems) that may influence the levels of ambient pollution 
exposure inside the home; these factors can all lead to an exposure misclassification. Another 
limitation is that the exposure is valuated only during adulthood not considering childhood and 
intrauterine environment. This time window could not be at the most etiologically relevant in 
relation to endometriosis disease pathogenesis.  
 
2.e  Conclusion 
This line of research has partially confirmed the role of endocrine disruptor of environmental 
pollutants on the gonadal axis. In fact, based on the available data obtained, an association between 
endometriosis and specific environmental pollutants cannot be excluded, even if at moderate and 
low level of evidence. In literature, this is the only study that tried to verify an association between 
endometriosis and air pollution-particulate matter exposure so larger trials and well conducted 
studies are demanding. 
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Fig. 2a Detailed flow chart 1.  
Original queries (n = 627) 
Scopus = 330 
Pubmed = 327 
Duplication of titles (n = 178) 
Excluded on first pass (n = 
337) 
 
Potentially relevant abstracts 
(n = 142) 
Scopus = 71 
Pubmed = 71 
Excluded on second pass (n = 
25) 
Duplication of data = 2 
Overlap cases and controls = 4 
No conservative statistic 
methods = 3 
Language restriction = 3 
Unpublished data = 1 
Pollutant no directly measured 
= 5 
Others= 6 
Elegible trials included in the systematic review (n = 
46) 
 
Dioxins-like compounds and PCBs:  n = 19 
Pthalathes: n = 9 
PCBs + pthalathes:  n = 1 
Organochlorine pesticides: 2 
Organochlorine pesticides + Dioxins/PCBs = 5 
Trace elements: n = 5 
Perflorochemicals:  n= 1 
Benzophenone: n = 1 
Particulate matter: n = 1 
Bisphenols n = 2 
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Fig. 2b Flow chart according PRISMA statement. 
Records identified through 
database searching 
(n = 657) 
Sc
re
en
in
g 
El
ig
ib
ili
ty
 
Id
en
ti
fi
ca
ti
o
n
 Additional records identified 
through other sources 
(n = 2) 
Records after duplicates removed 
(n = 481) 
Records screened 
(n =481) 
Records excluded 
(n =339) 
Full-text articles assessed 
for eligibility 
(n = 71) 
Full-text articles excluded, 
with reasons 
(n =25) 
Studies included in 
qualitative synthesis 
(n = 46) 
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TAB 1. 
Summary of study examining the involvement of environmental pollutant on the pathogenesis of endometriosis. The paper has been classified 
according the type of pollutant involved. 
 
Pollutant 
Author, 
Year, (ref) 
Study 
design 
Population Diagnosis method 
ON 
Score 
Method 
(pollutant 
analysis)  
Exposure Exposure evaluation 
Confounders 
adjusted for 
Results: effect estimation 
   
Country Individuals 
       
Dioxins and 
PCB            
 
Martinez-
Zamora et al. 
2015 
Case 
control 
Spain 
30 cases 
30 controls 
Laparoscopy and 
histology (DEND)  
7 
HR-
GC/HR-MS 
Omentum  
7 PCDDs 
10 PCDFs  
12 DLPCBs   
Breastfeeding 
2,3,4,7,8-PeCDF, 2,3,7,8-
TCDD, 1,2,3,7,8-PeCDD 
were significantly higher in 
patients with DIE 
 
Dioxins and DL-PCBs (PCB-
114; PCB-156; PCB-189; 
PCB-126) were significantly 
higher in patients with DIE 
 
 
Buck Louis et 
al. 2012 
Matched 
Cohort 
USA 
Operative 
cohort: 
190 cases 
283 
controls 
 
Population 
cohort: 
14 cases 
Laparoscopy and 
histology (operative 
cohort) 
 
Magnetic resonance 
(population cohort) 
 8 
 GC/HRMS 
electronic 
capture 
detector 
Serum  
Omentum 
PBDEs: 47, 99, 100, 
153, 154, 209;  
DLPCBs: 
114,118,156, 167,  
189. 
NDLPCBs: 18, 28, 44, 
49, 52, 66, 74, 87, 99, 
101, 128, 138, 146, 
149, 151, 153, 157, 
Age  
BMI  
Breastfeeding 
Lipids 
Codipine  
 
Crude OR significant for 
PCB 28,151,201  
PCBE 47 with reduced ORa 
PCBs 74,156 with reduced 
ORa 
PCB 153 showed a 
significant OR when 
breastfeeding was removed 
from the model  
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113 
controls 
170, 172, 177, 178, 
180, 183, 187, 194, 
195, 196, 201, 206, 
209. 
 
Vichi et al. 
2012 
Case 
control 
Italy 
63 cases 
63 controls 
Laparoscopy and 
histology 
 7 
 HR-GC/ 
Ion trap MS 
Serum 
analysis 
NDL PCB: 28, 52, 
101, 138, 153, 170, 
180  
DL PCB 105, 118, 
156, and 167.   
Breastfeeding 
and Lipid  
PCBs 118, 138, 153, 170, 
180 are associated with a 
significant increased risk of 
endometriosis 
 
Cai et al. 
2011 
Case 
control  
Japan 
10 cases 
7 controls  
Laparoscopy  5 
GC/HR-
MS  
Peritoneal 
fluid Serum  
Dioxin compounds:  
7 PCDDs; 10 PCDF 
and all dioxin like 
PCBs 
Lipid  
Higher levels of dioxin TEQ 
(PCDDs and PCDFs) in 
peritoneal fluid of 
endometriosis patients (OR: 
2.5; 95% CI: 1.17–5.34; p : 
0.035). 
No differences in serum 
 
Trabert et al. 
2010 
Case 
control  
USA 
251 cases 
538 
controls 
Laparoscopy (cases) 
Interview (controls) 
 9 
HR-
GC/HR-MS 
Serum 
analysis 
18 NDLPCBs: 18, 28, 
44, 49, 52, 66, 74, 99, 
138,  153, 170, 180, 
187, 194, 196, 201, 
206, and 209 
2 DLPCBa: (118, 156) 
Breastfeeding  
Lipid  
No statistical differences 
 
Sisma et al. 
2010 
Case 
control 
Belgium 
96 cases 
105 
controls 
Laparoscopy and 
histology 
 7 CALUX  
Serum 
analysis  
Dioxin compounds 
 
Increased risk of 
endometriosis (OR: 2.5; 95% 
CI: 1.17–5.34; P =  0.035) 
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Roya et al. 
2009 
Case 
control 
India 
86 cases 
91 controls 
Laparoscopy   5 
GC flame 
ionization 
detector  
Plasma 
analysis 
PCB 1, 5, 29, 98   
Significant increase in 
endometriosis group, related 
with stage   
 
Porpora et al. 
2009 
Case 
control 
Italy 
80 cases 
78 controls 
Laparoscopy and 
histology 
8 
CALUX 
HRGC/MS 
ion trap 
Serum 
analysis 
DLPCBs 
(105,118,156,167) 
NDLPCBs 
(28,52,101,138,153,16
7, 170-180)  
Dioxin compounds;  
 
Age, smoking 
habits, BMI, 
Weight changes 
DL-PCB 118 (OR = 3.79; 
95% CI 1.61-8.91);  
NDL-PCB 138 (OR = 3.78; 
95% CI 1.60-8.94);  
NDL - PCB 153 (OR = 4.88 
95% CI 2.01 -11.0);  
NDL-PCB 170 (OR = 3.52; 
95% CI 2.01-11.0);  
NDL PCB 180 (OR = 3.05 
(1.25–7.42) 
Total PCBs (OR = 5.63; 95% 
CI 2.25-14.1)    
 
Niskar et al. 
2009 
Case 
control 
Usa 
60 case 
64 controls 
Laparoscopy and 
histology  
8 
HRGC/ 
HRMS  
Serum 
analysis 
3 PCDD; 2 PCDF; 
DLPCBs (118,126, 
156,169); NDLPCBs 
(138,153,180); 
ppDDE; 
Lipid analysis 
and breast 
feeding 
No significant differences 
 
Tsuchiya et 
al. 2007 
Case 
control 
Japan 
79 cases  
(31 stage I-
II) (48 
stage III 
IV) 
59 controls 
Laparoscopy 7 GS/HRMS 
Serum 
analysis  
8 PCDDs 
10 PCDFs 
4 DL PCBs  
36 NDLPCBs 
Lipid analysis No significant differences  
 
Hoffman et 
al.. 2007 
Cohort USA 
79 cases 
864 
controls 
 
Questionnaire  
GC/ 
electron 
capture 
detection 
Serum 
analysis 
PBBs 
PCBs 
Age 
Household 
income, 
Menopausal 
status, 
PBB levels 
Increased incidence of 
endometriosis among women 
exposed to moderate PCB  
and high PCB 
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PCB level 
 
 
Porpora et al.  
2006 
Case 
control 
Italy 
40 cases 
40 controls 
Laparoscopy 8 
HRGC/MS 
ion trap 
Serum 
analysis 
2 DLPCB (118, 156)  
6 NDL (28, 52, 101, 
138, 153, 180) 
metabolic 
disease, 
gravidity, 
parity, weight 
changes 
Significant increase serum 
concentration of PCBs  in 
patients with endometriosis 
 
Quaranta et 
al, 2006  
Case 
control 
Italy 
10 cases 8 
controls 
Laparoscopy 6 
HRGC/MS 
ion trap 
Serum 
analysis 
1 DLPCB (118) 2 
NDLPCB (138,153)  
p,p'-DDE 
 
Significant increase serum 
concentration of PCB 
118,138, 153 and p,p'-DDE 
in patients with 
endometriosis 
 
Reddy et al. 
2006a 
Case 
control 
India 
85 cases  
135 
controls 
Laparoscopy  7 GC 
Plasma 
analysis 
PCB: 1, 5, 29; 98 (no 
coplanar)  
 
 
PCBa 1, 5, 29 98 higher in 
cases  
 
 
Buck Louis et 
al. 2005 
Case 
control 
USA 
32 cases 52 
controls 
Laparoscopy 9 
GC/electro
n capture 
detection 
Serum 
analysis 
7 DLPCBs (105, 114, 
118, 126, 167, 169, 
189)   55 NDLPC 
 
Borderline significance for 
anti-estrogenic PCBs (p: 
0,08) that are lower in 
endometriosis; no differences 
for estrogenic PCBs 
 
Heilier et al 
2005 
Case 
control 
Belgium 
25 END  
25 DEND 
21 controls 
END:laparoscopy 
DEND:histology 
6 GC/HR-MS 
Serum 
analysis 
17 PCDD/Fs, 12 
dioxin like PCBs 
standardization 
for BMI and 
age 
Dioxin like PCBs were 
significantly higher in 
adenomyiosis; PCDD/PCDF 
were significantly higher in 
cases than controls; 
significantly increase risk of 
adenomyiosis and 
endometriosis 
 
Heilier et al. 
2004 
Case 
control 
Belgium 
10 DEND   
7 END 
10 controls 
END:laparoscopy 
DEND:histology 
6 GC/HR-MS 
Serum 
analysis 
DLPCBs (118)  
NDLPCBs (3, 8, 28, 
52, 101, 153, 180, 194, 
206, 209) 
Age 
serum levels of all PCBs 
analysed significantly higher 
in patients with adenomyosis 
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De Felip et al. 
2004 
Case 
control 
Italy/Bel
gium 
23 cases  
17 controls 
Laparoscopy and 
histology 
6 GC-HRMS 
Serum 
analysis 
17 PCDD/PCDFs, 12 
dioxin-like PCBs  
No significant difference in 
cases and controls; lower 
body burden  levels in Italian 
population 
 
Fierens et al. 
2003 
Case 
control 
Belgium 
10 cases  
132 control 
Questionnaire  8 GC.HRMS 
Serum 
analysis 
17 PCDD/Fs  
11 NDLPCBs 
(3,8,28,52,10,138,153,
180,194,206,209),  
5 DLPCBs (77, 81, 
118,126)  
 
no differences between 
groups in terms of  PCDD/Fs 
and coplanar  PCBs d PCBs 
in cases and controls; 12 
PCB markers were slightly 
lower in endometriosis 
 
Eskenazi et al. 
2002 
Cohort Italy 
19 cases  
277 
controls 
(14 surg 
cases 
39 surg 
contr). 
Laparoscopy no in all 
cases 
 7 GC/ HRMS  
Serum 
analysis 
TCDD 
 
not significant: RRR 1.1 
(90% CI 0.2-7.8) in group 
20-100 ppt; RRR 3.6 (90% 
CI 0.5-27.0) in >100 ppt 
doubled not significant risk 
for endometriosis among 
woman with TCDD >100ppt. 
 
Pauwels et al. 
2001 
Case 
control 
Belgium 
42 cases 
27 controls 
Laparoscopy  8 
CALUX  
GC-ECD 
Serum 
analysis 
Dioxins compounds 
3 NDLPCBs 
(138,153,180) 
BMI  
Alcohol intake  
No statistical differences  
 
Lebel et al. 
1998 
Case 
control 
Canada 
86 cases 
70 controls 
Laparoscopy 7 GC/ ECD 
Plasma 
analysis 
12 NDLPCBs (28, 52, 
99, 101, 105, 128, 138, 
153, 170, 180, 183, 
and 187)  
2 DLPCBs (118, 156) 
 
Age  
BMI 
No statistical differences 
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Mayani et al. 
1997 
Case 
control 
Israel 
44 cases 
35 controls 
Laparoscopy 4 GC/ MS 
Blood 
analysis 
TCDD  lipid 
Non significant OR 7.6 (95% 
CI 0.87–169.7). 
 
Gerhard and 
Runnebaum 
1992 
Case 
control 
Germany 
28 cases 
441 control 
Laparoscopy     n.a. 
Blood 
analysis 
NDL-PCB 
128,153,180 
 
  
PCB (128, 153, 180) 
significantly higher among 
endometriosis group 
Phthalates   
          
 
Huang et al. 
2014 
Case 
control 
Taiwan 
44 cases 
(16 adeno-
myosis) 
69 controls 
Laparoscopy and 
histology 
7 
LC/ 
Electro- 
spray 
ionization  
MS 
Urinary 
phthalates 
metabolites 
MMP, MEP, MnBP, 
MBzP, MEHP, 5oxo-
MEHP, 5OH-MEHP 
 
Endometriosis/adenomyosis  
women showed a marginally 
increased level of urinary 
MEHP only  
 
Buck Louis et 
al. 2013 
Matched 
cohort 
USA 
190 cases 
283 
controls 
(operative 
cohort) 
 
14 cases 
113 
controls 
(population 
cohort) 
Laparoscopy/Surgery  
and histology 
(operative cohort) 
 
MRI  
(population cohort) 
5 
Enzymatic 
deconjuga-
tion and 
solid phase 
extraction 
Urinary 
phthalate 
metabolites 
MECPP, MCMHP, 
5oxo-MEHP, 5OH- 
MEHP, MEHP; 
mCPP, MMP, MEP, 
MiBP, MnBP, MCHP, 
MBzP, MNP, MOP, 
MBP BPA 
Age  
BMI Creatinine 
Operative cohort no 
difference for all pollutant 
analysed 
Population cohort: MECPP 
MEHP, 5 OH MEHP, 5 oxo 
MEHP: 1.7 fold or higher 
odds of endometriosis 
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Upson et al. 
2013 
Case 
control 
USA 
92 cases 
195 
controls 
Laparoscopy/ Surgery 7 LC-MS 
Urinary 
phthalate 
metabolites 
MEHP, 
5OH-MEHP, 5oxo- 
MEHP, MECPP, 
MBzP, MEP, MiBP, 
MnBP 
Age 
Education 
Smoking 
Alcohol  
Inverse associatiotn MEHP 
(4th vs 1st quartiles (aOR 
0.3, 95% CI: 0.1–0.7)  
 
Kim et al. 
2011 
Case 
control  
Korea  
97 cases 
169 
controls  
Surgical and histology   8  LC- MS 
Plasma 
analysis  
MEHP, DEHP 
Pregnancy 
BMI 
MEHP Elevated in 
endometriosis women OR 
1.020 (CI 95% 1.003–1.038  
p = 0.20)  
 
Weuve et al. 
2010 
Cross-
sectional 
 USA 
1020 
controls  
87 cases 
Questionnaire      
Phthalate 
metabolites 
MEHP, MBP, MEP, 
MBzP, 5OH-MEHP, 
5oxo-MEHP 
Age  
Ethnicity 
Age menarche 
Pregnancy 
Breast feeding  
Positive association for MBP 
and endometriosis or 
leiomymatosis and weak 
inverse association of MEHP 
and endometriosis or 
leiomymatosis  
 
Huang et al 
2010 
Case 
control 
Taiwan 
29 controls 
29 
endometr. 
16 
adeomios 
Surgery and histology   LC-MS Urine 
MMP, MEP, MnBP 
MBzP, MEHP, 5oxo-
MEHP and 5OH-
MEHP 
 
Creatinine adjusted MnBP 
higher in cases 
 
Roya et al. 
2008 
Case 
control  
India 
99 cases 
135 
controls 
Laparoscopy 5 HP-LC 
Serum 
analysis  
DMP, DEP, DnBP 
BBP. BEHP 
 
DMP, DEP, DnBP  
BBP. BEHP higher in study 
group; each compound 
significantly correlated with 
endometriosis severity 
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Reddy et al. 
2006b 
Case 
control 
India 
49 cases 
38 controls 
Laparoscopy 6 
HP-LC -
GC 
Plasma 
analysis 
DnBP, BBP, DnOP  
DEHP  
DnBP, BBP, DnOP DEHP 
higher in endometriosis 
groups and significantly 
correlated with endometriosis 
severity 
 
Reddy et al. 
2006a 
Case 
control 
India 
85 cases  
135 
controls 
Laparoscopy  7 GC 
Plasma 
analysis 
DnBP; DEHP; DnOP. 
BBP.  
Phatelates esters higher in 
cases 
Higher value of both 
pollutant in advanced stage. 
 
Cobellis et al. 
2003 
Case 
control 
Italy 
35 cases 
24 controls 
Laparoscopy 7 HP-LC 
Serum 
Peritoneal 
fluid  
DEHP MEHP 
 
Significantly higher serum 
levels of DEHP in patients 
with endometriosis  
Organochlori
ne pesticides             
 
Upson et al. 
2013 
Case 
control 
USA 
248 cases 
538 
controls 
Laparoscopy  7 
Isotope-
dilution 
GC-HR-
MS 
Serum 
analysis  
β‑hexachlorocyclohex
ane (β‑HCH), 
γ‑hexachlorocyclohex
ane (γ‑HCH), 
heptachlor 
epoxide, 
oxychlordane, 
trans‑nonachlor, 
two isomers of 
dichlorodiphenyltrichl
oroethane 
(p,p´‑DDT, 
o,p´‑DDT), 
dichlorodiphenyldichl
oroethylene 
(p,p´‑DDE), 
dieldrin, 
hexachlorobenzene, 
Age, Reference 
date 
Year, Smoking, 
Alcohol, 
Education,  
Total lipids,  
Ethnicity. 
β‑HCH and mirex associated 
with endometriosis. Stronger 
association between β‑HCH 
and in subgroups affected by 
ovarian endometriosis   
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and mirex. 
 
Buck Louis et 
al. 2012 
Matched 
Cohort 
USA 
Operative 
cohort: 
190 cases 
283 
controls 
 
Population 
cohort: 
14 cases 
113 
controls 
Laparoscopy/ Surgery 
and histology 
(operative cohort) 
 
Magnetic resonance 
(population cohort) 
8 
 GC/HRMS 
electronic 
capture 
detector 
Serum  
Omentum 
OCPs: HCB, HCH, γ-
HCH, β-HCH, 
oxychlordane, cis- and 
trans-nonachlor, cis- 
and trans-chlordane, 
p,p´-DDT p,p´-DDE 
o,,p´-DDT 
Age  
BMI  
Breastfeeding 
Lipids 
Codipine  
 
γ-HCH associated with 
endometriosis in operative 
cohort 
β-HCH associated with 
endometriosis in population 
cohort 
 
 
Cooney et al. 
2010 
Case 
control 
USA 
29 cases 
51 controls 
Laparoscopy 8 
GC 
electron-
capture  
Serum 
analysis 
Aldrin,  
β-BHC; DDE; HCB, 
mirex, trans-nonachlor  
Total serum 
lipids 
Smoking 
Other 
organochlorine 
pesticides  
HCB associated with 
increased odds of 
endometriosis  
 
Porpora et al. 
2009  
Case 
control 
Italy 
80 cases 
78 controls 
Laparoscopy and 
histology 
8 
HRGC/MS 
ion trap 
Serum 
analysis 
HCB; pp‟ DDE 
Age, smoking 
habits, BMI, 
Weight changes 
No statistical differences     
 
Quaranta et 
al, 2006 
Case 
control 
Italy 
10 cases 8 
controls 
Laparoscopy and 
histology  
6 
HRGC/MS 
ion trap 
Serum 
analysis 
p,p'-DDE  
significant increase serum 
concentration of p,p'-DDE in 
patients with endometriosis  
22 
Lebel et al. 
1998 
Case 
control 
Canada 
86 cases 
70 controls 
Laparoscopy 7 GC/ ECD 
Plasma 
analysis 
α chlordane, γ 
chlordane, p,p´ DDT, 
p,p‟ DDE, aldrin, β 
HCH, HCB, mirex, 
oxychlordane, cis-
nonachlor, trans-
nonachlor  
Age  
BMI 
No statistical differences 
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 24 
Gerhard and 
Runnebaum 
1992 
Case 
control 
Germany 
28 cases 
441 control 
Laparoscopy/Surgery    n.a. 
Blood 
analysis 
HCH, HCB,  
DDT, DDE, DDD 
  No association was reported  
Trace 
elements            
 
Turgut et al. 
2013 
Case 
control 
Turkey 
31 cases 
41 controls 
Laparoscopy/surgery 
and histology 
5 
 
Copper: 
Specto-
metry 
 
Ceruloplas
min; 
nephelo-
metric 
assay  
 
 
Serum 
analysis 
copper and 
ceruloplasmin  
Cu (μg/ml): 1088.00 ± 
273.58 811.20 ± 265.77 < 
0.001 
 
Silva et al. 
2013 
Case 
control 
Sri Lanka 
50 cases 
50 controls 
Laparoscopy/Surgery  5 
The total-
reflection 
X-ray 
fluorescenc
e 
 
Atomic 
absorption 
spectroscop
y 
Blood 
analysis 
lead; nichel; cadmium 
 
Nickel higher in 
endometriosis group  
Lead: not significant  
Cadmium: not significant 
 
Pollack et al 
2013 
Matched 
cohort 
USA 
Operative 
cohort: 
190 cases 
283 
controls 
 
Population 
Laparoscopy/ Surgery 
and histology  
(operative cohort)  
 
MRI (population 
cohort)  
8 ICP-MS 
Blood and 
urine 
analysis 
Urine: antimony, 
arsenic (As), barium, 
beryllium, cadmium, 
cesium, chromium, 
cobalt (Co), copper, 
lead, manganese, 
mercury, 
Age 
BMI, Smoking,  
Race, Vitamin 
use Creatinine, 
Parity/gravidity 
In the operative cohort, blood 
cadmium was associated with 
a reduced odds of diagnosis 
(aOR = 0.55; 95% CI: 0.31, 
0.98), while 
urinary chromium and copper 
reflected an increased odds 
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cohort: 
14 cases 
113 
controls 
molybdenum, nickel 
(Ni), tellurium, 
thallium, tin, tungsten, 
uranium and zinc.  
Blood: Cadmium, lead 
(aOR = 1.97; 95% CI: 1.21, 
3.19 
 
Heilier et al. 
2006 
Case 
control 
Belgium 
119 cases  
25 controls 
Laparoscopy 5 
electro 
thermal 
graphite 
furnace 
atomic 
absorption 
spectro-
metry 
Serum and 
urine for 
cadmium, 
serum for 
lead 
cadmium, lead  
No correlation for cadmium; 
lower serum levels of lead in 
endometriosis 
 
Heilier et al. 
2004 
Case 
control 
Belgium 
38 cases  
(25 
endometrio
sis13 
adeno-
myosis) 21 
controls 
laparoscopy in cases, 
controls clinical exam 
7 
electrother
mal 
graphite 
furnace 
atomic 
absorption 
spectrometr
y 
Serum and 
urine 
analysis 
cadmium Age Smoking  
No difference in serum 
among the groups; in urine, 
not difference significant, but 
the mean was slightly higher 
in adenomyosis 
Perfluoroche
micals            
 
Buck Louis et 
al. 2012 
Cohort USA 
Operative 
cohort  
190 cases 
283 
controls 
 
Population 
Laparoscopy and 
histology (operative 
cohort) 
 
MRI 
(population cohort) 
5 HP-LC/MS  
Serum 
analysis 
PFDA, PFHxS, PFNA, 
PFOA, PFOS, 
PFDoDA, PFHpA, 
PFOSA, PFUnDA  
Age  
BMI 
Parity  
Serum perfluorooctanoic acid 
and perfluorononanoic acid 
associated with 
endometriosis in operative 
cohort  
PFOS and PFOA increased 
the odds of endometriosis in 
64 
 
cohort 
14 cases 
113 
controls 
advanced stages in both 
population. 
Results were moderately 
attenuate with parity 
adjustment 
Benzophenone 
           
 
Kunisue et al. 
2012 
Cohort USA 
Operative 
cohort 
190 cases 
283 
controls 
 
Population 
cohort 
14 cases 
127 
controls 
Laparoscopy 
(operative cohort) 
 
MRI 
(population cohort) 
5 LC-MS 
Urine 
analysis 
2 OH-4MeO-BP, 
2,4 OH-BP,  
2,2‟OH-4MeO-BP 
2,2‟,4,4‟OH-BP  
4 OH-BP 
Site 
Hair colour  
2,4OH-BP increase the odds 
of an endometriosis in the 
operative cohort 
Bisphenols  
           
 
Buck Louis et 
al. 2013 
Matched 
cohort 
USA 
190 cases 
283 
controls 
(operative 
cohort) 
 
14 cases 
113 
controls 
(population 
cohort) 
Laparoscopy 
(operative cohort) 
 
MRI  
(population cohort) 
5 
HP-LC+ 
MS 
 
 
BPA 
Age  
BMI Creatinine 
Operative cohort no 
difference for all pollutant 
analysed 
Population cohort: MECPP 
MEHP, 5 OH MEHP, 5 oxo 
MEHP: 1.7 fold or higher 
odds of endometriosis 
 
Cobellis et al. 
2009 
Case 
control 
Italy  
58 cases 
11 controls 
Laparoscopy 4 HPLC-MS  
Serum 
analysis  
BPA and BPB 
 
BPA and BPD not detected 
in control group. No odds 
provided 
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Particulate 
matter 
           
 
Mahalingaiah 
et al. 2014 
Cohort USA 
Total 
cohort 
84060  
Questionnaire and 
medical record 
8 
Proximity 
to 
roadways 
 
Estimated 
outdoor 
levels of 
particulates 
 
Air pollution  
PM 10; PM 2.5; PM 
10-25;  
Age,  
Calendar time 
Race, 
BMI, Smoking, 
Parity  
Oral 
Contraception. 
Menarche, 
Infertility 
Rotating shift 
work 
Region 
No association observed 
BBP:Butyl benzyl phthalate; BEHP: Bis (2ethylexyl) phthalates; β-BHC beta-benzene hexachloride; BPA: Bisphenol A; BPB: Bisphenol B; CHP: chlorinated pesticides; CX 
Calux assay; DEND: deep endometriosis; DL: Dioxin like; DEHP: di-2 ethylhexyl phthalate; DEP: Diethyl phthalates; DDE: dichloro-2,2-bisp-chlorophenyl ethylene;  DMP: 
Dimethyil phthalate; DnBP: Di-n-butyl phthalates, DnOP: d-octyl phthalates; ECD: Electronic capture detector; FID: flame ionization detector; GC: Gas chromatography; LC 
liquid chromatography; HP: High performance; HR: high resolution; ICP-MS: Coupled plasma-mass spectrometry  NDL: Non dioxin like; MCMHP: mono-2-carboxy methyl 
hexyl phthalate; MCHP : monocyclohexyl phthalates; MCPP: mono (3-carboxypropyl) phthalate; MECPP: mono-(2-ethyl-5-carboxypentyl) phthalate; mono-(2-ethyl-5-
carboxypentyl) phthalate; MBP: mono butyl phthalate MBzP: mono-benzyl phthalates; MS: mass spectrometry; MEHP: mono-ethylhexyl phthalate; 5OH-MEHP: mono-(2-ethyl-
5-hydroxyhexyl) phthalate; 5oxo-MEHP: mono (2 ethyl-5-oxohexyl) MEHP; MEP: mono-ethyl phthalate; MiBP: mono-iso-butyl phthalate; MnBP: mono-n-butyl phthalates;  
MMP: mono methyl phthalate; MNP: monoisonoyl phthalate; MOP: monooctyl phthalate; ON score: Ottawa New Castle scoring; TCDD: 2,3,7,8 tetrachlorodibenzo-p-dioxin; 
HCB hexachlorobenzene ; HCH; hexachlorocyclohexane; Tetrachlorodiphenylethane DDD; p,p‟ DDT:  dichlorodiphenyltrichloroethane; p,p‟ DDE 
dichlorodiphenyldichloroethylene; OCP: Organochinolone pesticides; ON: Ottawa Newcastle PBB: polybrominated biphenyls; PCP: pentachlorophenole PBDE: polybrominated 
diphenyl ether congeners, PCB: polychlorinated biphenyls 
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Abbreviation list per contaminants 
 
Perfluorochemicals:  
PFC: perfluorochemicals  
PFDA: perfluorodecanoic acid  
PFHxS: perfluorohexane sulfonic acid  
PFNA: perfluorononanoic acid 
PFOA: perfluorooctanoic acid 
PFOS: perfluorooctane sulfonic acid 
PFDoDA: perfluorododecanoic acid 
PFHpA: perfluoroheptanoic acid 
PFOSA: perfluorooctanesulfonamide 
PFUnDA: perfluoroundecanoic acid 
 
Dioxins 
TCDD :2,3,7,8 tetrachlorodibenzo-p-dioxin 
PCDDs: polychlorinated dibenzo-p-dioxins  
1,2,3,7,8-PeCDD: 1,2,3,7,8-pentachlorodibenzo-p-dioxin 
PCDFs: polychlorinated dibenzofurans  
2,3,4,7,8 PeCDF: 2,3,4,7,8- polychlorinated dibenzofurans  
 
Polychlorinated biphenyls. 
PCB: polychlorinated biphenyls 
DL-PCB: dioxin like polychlorinated biphenyls 
NDL-PCB: non-dioxin-like PCBs 
PBDE: polybrominated diphenyl 
 
Phthalate compounds 
MEHP: mono-ethylhexyl phthalate 
5OH-MEHP: mono-(2-ethyl-5-hydroxyhexyl) phthalate  
5oxo-MEHP: mono (2 ethyl-5-oxohexyl) MEHP 
MEP: mono-ethyl phthalate 
MiBP: mono-iso-butyl phthalate 
MnBP: mono-n-butyl phthalates  
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MMP: mono methyl phthalate 
MNP: monoisonoyl phthalate 
MOP: monooctyl phthalate 
 
Bisphenols 
BPA bisphenol type A 
BPB: bisphenol type B 
toxic equivalent factor (TEF) 
 
Organocholorine pesticides 
HCB hexachlorobenzene 
HCH; hexachlorocyclohexane 
Tetrachlorodiphenylethane DDD 
p,p‟ DDT:  dichlorodiphenyltrichloroethane 
p,p‟ DDE dichlorodiphenyldichloroethylene 
 
Benzophenone derivates  
2OH-4MeO-BP: 2-hydroxy-4-methoxybenzophenone 
2,4 OH-BP:2,4-dihydroxybenzophenone 
2,2‟OH-4MeO-BP:2,2‟-dihydroxy-4-methoxybenzophenone 
2,2‟,4,4‟OH-BP 2,2‟,4,4‟-tetrahydroxybenzophenone  
4OH-BP: 4-hydroxybenzophenone 
 
Particulate matter 
PM 2.5; Particulate matter 2.5mm 
PM 10: Particulate matter 10 mm 
PM 25 Particulate matter 25mm 
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Table: PCBs classification 
Dioxin like PCBs 77, 81, 105, 114, 118, 123, 126, 156, 157, 167, 
169, 189 
Anti estrogenic PCBs (Cooke et al. 2011) 105, 114, 126, 169 (Cooke et al. 2001) (Louis et 
al., 2005) 
118, 138, 163, 170, 180, 187, 194, 199 203 
(Zhang et al., 2014) 
Estrogenic PCBs (Cooke et al. 2011) 18, 31, 44, 48, 52, 70, 99, 101, 126, 136, 153,188 
Cooke et al. 2001 (Louis et al., 2005) 
18, 28, 49, 52, 99, 101, 103, 110, 128 (Zhang et 
al., 2014) 
 
Table: Analysis of cases and controls  
Laparoscopy adopted in both cases and 
controls 
Mayani et al. 1997 
Lebel et al. 1998 
Pauwels et al. 2001 
Eskenazi et al. 2002 
De Felip et al. 2004 
Louis et. al. 2005 
Porpora et al. 2006 
Quaranta et al. 2006 
Reddy et al. 2006  
Tsuchiya et al. 2007 
Niksar et al. 2009 
Porpora et al. 2009  
Roya et al. 2009  
Simsa et al. 2010 
Martinez-Zamora et al. 2015 
Laparoscopy adopted only for cases Gerhard et al. 1999 
Heiler et al. 2005 
Heiler et al. 2004 
Heiler et al. 2007 
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Trabert et. al 2010 
Other diagnostic method  Carpenter et al. 2001 (electronic database) 
Carpenter et al 2003 (electronic database) 
Fierens et al. 2003 (questionnaire)  
 
No specified diagnostic method Gerhard et al. 1992 
 
Table: Definition of the cases  
Gold standard 
(Laparoscopy/surgery 
and histology) 
Dioxins/ PCBs De Felip et al. 2004; Porpora et al. 2006; 
Quaranta et al. 2006; Niksar et al. 2009; 
Porpora et al. 2009; Simsa et al. 2009; Buck 
Louis et al. 2012; Vichi et al. 2012; Martinez 
and Zamora et al 2015 
 Phtalates  Huang et al. 2014; Buck Louis et al. 2013; Kim 
et al. 2011 
 Organochlorine 
pesticides 
Buck Louis et al. 2012; Porpora et al. 2009; 
Quaranta et al. 2006 
 Trace elements Turgut et al. 2013; Pollack et al. 2013  
Laparoscopy/surgery Dioxins/ PCBs Mayani et al. 1997; Lebel 1998; Gerhard et al. 
1992; Pauwels  et al. 2001; Heiler et al. 2004; 
Heiler et al. 2005; Buck Louis et al. 2005; 
Reddy et al. 2006, Tsuchiya et al. 2007; Roya et 
al. 2009; Cai et al. 2011; Trabert et al. 2010 
Laparoscopy/surgery Pthalates  Upson et al. 2013; Huang et al. 2010; Roya et 
al. 2008; Reddy et al. 2006; Reddy et al. 2006; 
Cobellis et al. 2003 
 Organochlorine 
pesticides  
Upson et al. 2013; Cooney et al. 2010; Lebel et 
al. 1998; Gerhard and Runnebaum 1992 
 Trace elements Silva et al. 2013 
Questionnarie Dioxins/PCBs Fierens et al. 2003; Hoffman et al. 2007 
 Phthalates Weuve et al. 2010  
  
Partially be laparoscopy Eskenazi et al. 2002 
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Chapter IV: Alternative research line 
 
In the last year, from April to December, the PhD student realized a period of fellowship at the 
“University Mangiagalli” in Milan. Here she had the opportunity of comparing the obstetric 
outcome of spontaneous pregnancies with those one derived from medical assisted procreation, 
approaching this topic by both a clinical and scientific point of view. As reported in recent 
literature, there are substantial differences between these pregnancies and the argument becomes 
even more controversial if considering the new technologies, such as frozen embryo transfer and 
blastocyst transfer. From this scientific background, the PhD student has decided to contribute to 
the realization of a systematic review of literature with a meta-analysis to check the actual state of 
art in matter of perinatal outcomes differences after blastocyst versus cleavage state transfer.  
Besides she has participated to the ideation, writing, start up and initial recruiting of a project called 
GENACOS (Impact of Gonadotropin GENetics Profile and OvArian Reserve on Controlled 
Ovarian Stimulation Outcomes). This two year study aimed at creating a predictive algorithm based 
on the ovarian reserve and the genetic profile of gonadotropins in order to customize the dose of 
gonadotropins during ovarian stimulation. It is a no profit study that is coordinated by Dr Enrico 
Papaleo (principal investigator) and is funded by an unrestricted grant by Merck. Its protocol has 
been approved by the ethical committee of coordinator and peripheral centers. 
The following paragraphs are dedicated to the results of the first study and will describe  
GENACOS protocol. 
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1. Does cryopreservation influence perinatal outcomes after blastocysts versus 
cleavage stage transfer? A systematic review and meta-analysis 
 
1.a  Introduction 
Since the first reports
 
(Hardarson et al., 2012; Maxwell et al., 2015) extended embryo culture is 
becoming a widespread approach in assisted reproductive technologies. Compared with traditional 
cleavage-stage embryo transfer, this procedure results in a sort of “natural selection” of the most 
viable embryos, more similar to what usually happens during spontaneous conception in which 
implantation occurs only when embryos are in an advanced developmental stage (Munne et al., 
2002).  
Despite theoretical advantages, the clinical efficacy of blastocyst transfer versus cleavage stage 
transfer is debatable. In fact, while a Cochrane meta-analysis reported increased clinical pregnancy 
and live birth rates after blastocyst transfer (Glujovsky et al. 2016), a more recent meta-analysis did 
not find any statistically significant differences in these ART outcomes between blastocyst and 
cleavage stage transfer (Martins et al., 2016).  
Data on the perinatal outcome of babies born after blastocyst transfer are even more controversial 
(Dar et al., 2014; Maheshwari et al., 2013). The first meta-analyses (Dar et al., 2014; Maheshwari 
et al., 2013) claimed that blastocyst transfer is associated with an increased risk of preterm births, 
very preterm births and congenital malformations. Subsequent studies did not confirm these 
observations (Chambers et al., 2015; Ishihara et al., 2014; De Vos et al., 2015; Oron et al., 2015). 
In fact, an analysis of 43,952 singleton deliveries after transfer of blastocysts or cleavage-stage 
embryos did not reveal an increased risk of preterm births in blastocyst pregnancies (Chambers et 
al., 2015). Similarly, a recent study of 277,402 embryo transfer cycles in Japan did not find any 
statistically significant increase in the risk of very preterm births and preterm births after blastocyst 
transfer (Ishihara et al., 2014). Finally, a study of the neonatal and perinatal outcomes of 30,566 
singletons did not identify any statistically significant differences in terms of congenital anomalies, 
or preterm and very preterm births between IVF carried out with cleavage-stage embryos and IVF 
carried out with blastocysts (Ginstrom Ernstad et al., 2016).  
The limit of previous meta-analyses on this topic (Dar et al., 2014; Maheshwari et al., 2013; 
Martins et al., 2016) is that they merged data from both fresh and frozen/thawed embryo transfers 
without considering the effect of cryopreservation on their results. 
The aim of our study was to evaluate whether cryopreservation could influence differences in 
perinatal outcomes between blastocyst and cleavage stage transfer. In detail, we performed a 
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systematic review and meta-analysis comparing perinatal outcomes after the transfer of blastocysts 
or cleavage-stage embryos in singleton pregnancies. We also carried out a subgroup analysis of 
fresh cycles alone. 
 
1.b  Methods 
Protocol, eligibility criteria, information sources and search 
This systematic review was conducted according PRISMA guidelines. We searched the MEDLINE 
(Pubmed), ISI WEB OF KNOWLEDGE and SCOPUS databases. We also searched the reference 
lists of relevant studies and reviews. Combinations of the following keywords and search terms 
were used: “blastocyst”, “cleavage stage embryo” “perinatal outcome”, “perinatal mortality”, 
“preterm birth” OR “premature birth”, “birth weight”, “congenital abnormalities” OR “congenital 
defect” OR “deformity” OR “birth defect”. No time or language restriction was adopted, and 
queries were limited to human studies. The reference lists of relevant reviews and articles were also 
hand-searched.  
 
Study selection, data collection and data items 
Three reviewers (A.C., R.B. and F.C.) evaluated titles and abstracts. Duplications were removed 
using Endnote online software. Disagreements were resolved by discussion between authors, and 
the involvement of the most experienced authors (C.A., S.G., G.D.). We included studies in which 
the perinatal outcomes of a singleton pregnancy born from blastocyst transfer were compared with 
the outcomes of cleavage stage transfer in infertile women. Case series, case report, books, congress 
abstracts and grey literature were not included in the analysis.  
 
Risk of bias, summary measures and synthesis of the results 
The risk of bias and quality assessment of the included studies were performed adopting the 
Newcastle-Ottawa Scale (NOS) (Wells et al., 2004). Three authors (A.C., R.B. and F.C.) 
independently assessed the risk bias for each study included. The most experienced authors (C.A, 
S.G and G.D.) resolved conflicts. The NOS score was used to evaluate studies included and each 
study was judged based on three issues: selection of the study group; comparability between groups; 
and ascertainment of exposed and not exposed cohorts (Wells et al., 2004).  Primary outcomes 
were: preterm births (live birth before 37 weeks of gestation) and low birth weight (<2,500g). 
Secondary outcomes were: very preterm births (live birth before 32 weeks of gestation); very low 
birth weight (<1,500 g); small for gestational age (SGA); large for gestational age (LGA); perinatal 
mortality; and congenital anomalies. Data were extracted independently by three reviewers (A.C., 
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R.B. and F.C.) and discrepancies were resolved by discussion with the most experienced authors 
(C.A., S.G. and G.D.). Publication bias of primary outcomes was assessed using funnel plots with 
the trim and fill method (Duval et al, 2006) and the Egger test (Egger et al., 1997). 
 
Statistical analysis  
Statistical analysis was carried out using Revman software (The Nordic Cochrane Centre, The 
Cochrane Collaboration. Review Manager version 5.3). Data were combined to a pooled odds ratio 
(OR). Meta-analysis was conducted using random-effect-model. Between-study heterogeneity was 
addressed using I
2 
which represents the percentage of total variation in the estimated effect across 
studies. An I
2 
value over 50% indicates substantial heterogeneity. P values <0.05 were considered 
statistically significant. 
 
1.c  Results 
Study selection and characteristics 
A total of 3,697 papers was identified and 339 duplications were removed using an EndNote online 
library. The titles and abstracts of 3,358 papers were scrutinized and 37 full papers were assessed 
for eligibility. Twenty-three papers were excluded. Specifically, the data of 2 papers could not be 
extracted (Wang et al. 2011; Sotiroska et al., 2015); 16 papers did not fulfil our inclusion criteria. 
Furthermore, data replication was detected in 4 papers (Oron et al., 2015; Kallen et al., 2010; 
Sazonova et al., 2012). In detail, Nakashima et al.
,
 Kallen et al., Sazanova et al. extracted newborn 
data from the same registry used more recently by Ginstrom Ernstad et al. (2016) and Ishihara et al 
(2014); Oron et al. (2014) reported similar data in two papers. Moreover, the studies by Makinen et 
al.(2013), Wikland et al.(2010) and Kaartinen et al. (2015) were not considered because they 
analysed the same population of other studies included. Among papers with data replication, we 
chose the studies with the largest number of observations (Oron et al., 2014; Ginstrom Ernstad et 
al., 2016; Ishihara et al., 2014). Twelve articles were included in the qualitative/quantitative 
analysis (Figure 1). The characteristics of the studies included in the present study are reported in 
Table 1.  
 
Risk of bias within the study  
Risk of bias was considered “low” for studies with a Newcastle-Ottawa Scale (NOS) score above 
7,“medium” for studies with a NOS score between 7 and 5, and “high” for studies a NOS score 
below 5 (Table 2).  
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Synthesis of results 
Preterm birth (<37 weeks) 
Preterm births were investigated in 11 studies (Maxwell et al., 2015; Chambers et al., 2015; 
Ishihara et al., 2014; Oron et al., 2014; Dar et al., 2013; Shchwarzler et al., 2004) (blastocyst 
transfer n = 89,709 vs cleavage-stage transfer n = 102,687). The overall OR did not reveal a 
significant increased risk of preterm birth after blastocyst transfer than after cleavage-stage transfer 
(OR 1.11, 95% CI 0.99 – 1.26, p = 0.08, I2 = 89%). Subgroup analysis of fresh cycles (blastocyst n 
= 30,177 vs cleavage stage n = 75,021) revealed a higher risk in blastocyst versus cleavage stage 
pregnancies (OR 1.18, 95% CI 1.06 – 1.32, p = 0.003, I2 = 69%) (Figure 2). 
 
Very preterm birth (<32 weeks)  
Very preterm birth was assessed in 8 studies (Kalra et al., 2012; Dar et al., 2013; Ginstrom Ernstad 
et al., 2016; Ishihara et al., 2010; De Vos et al., 2015; Oron et al., 2015; Maxwell et al., 2015) 
(blastocyst n = 60,488 vs cleavage stage n = 86,500). Based on overall OR, there were no 
significant differences between blastocyst and cleavage-stage pregnancies (OR 1.05, 95% CI 0.90 – 
1.23, p = 0.54, I
2
 = 48%). Subgroup analysis of fresh cycles (blastocyst n = 29,571 vs cleavage 
stage n = 74,171) showed a higher risk of very preterm births after blastocyst than after cleavage-
stage transfer (OR 1.16, 95% CI 1.02 – 1.32, p = 0.03, I2 = 17%) (Figure 3). 
 
Small for gestational age 
Small for gestation age was analysed in 7 studies (Chambers et al., 2015; Ishihara et al., 2014; Oron 
et al., 2014; Fernando et al., 2012; Kalra et al., 2012; Zhu et al., 2014) (blastocyst n = 83,123 vs 
cleavage stage n = 93,369). Significantly fewer SGA babies was born after blastocyst than after 
cleavage stage transfer (OR 0.78, 95% 0.68 – 0.90, p = 0.0005, I2 = 84%). Subgroup analysis of 
fresh cycles (blastocyst n = 24,138 vs cleavage stage n = 65,977) showed a lower risk of SGA after 
blastocyst than after cleavage stage pregnancy (OR 0.83, 95% CI 0.74 – 0.93, p = 0.001, I2 = 35%) 
(Figure 4). 
 
Large for gestational age 
Large for gestational age was addressed in 5 studies (Zhu et al., 2014; Fernando et al., 2012; Oron 
et al., 2014; Ginstrom Ernstad et al., 2016; Ishihara et al., 2014) (blastocyst n = 40,299 vs cleavage 
stage n = 45,929). The overall OR showed a higher number of LGA births in blastocyst than in 
cleavage stage pregnancies (OR 1.23, 95% CI 1.01 – 1.50, p = 0.04, I2 = 79%). Subgroup analysis 
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of fresh cycles (blastocyst n = 9,382 vs cleavage stage n = 33,600) did not result in a statistical 
significant difference between groups (OR 1.15, 95% CI 0.97 – 1.36, p = 0.11, I2 = 44%) (Figure 5). 
 
Low birth weight (<2500 kg) 
Low birth weight was investigated in 9 studies (Chambers et al., 2015; Ishihara et al., 2014; De Vos 
et al., 2015; Oron et al., 2014; Dar et al., 2013; Kalra et al., 2012; Shwarzler et al., 2004) 
(blastocyst n = 86,912 vs cleavage stage n = 100,623). The overall OR did not differ between 
blastocyst and cleavage stage pregnancies (OR 0.92, 95% CI 0.82 – 1.04, p = 0.20, I2 = 86%). 
Subgroup analysis of fresh cycles (blastocyst n = 27,928 vs cleavage stage n = 73,231) did not 
reveal any statistical differences between groups (OR 1.01, 95% CI 0.92 – 1.11, p = 0.89, I2 = 53%) 
(Supplemental data 1). 
 
Very low birth weight (<1500 kg) 
Very low birth weight was evaluated in 6 studies (Dar et al., 2013; Fernando et al., 2012; Oron et 
al., 2014; Ishihara et al., 2014; De Vos et al., 2015; Ginstrom Ernstad et al., 2016) (blastocyst n = 
44052 vs cleavage stage n = 53439). Analysis of the overall effect size did not reveal any 
differences between blastocyst and cleavage stage pregnancy (OR 0.93, 95% CI 0.82 – 1.06, p = 
0.29, I
2
 = 0%). Subgroup analysis of fresh cycle (blastocyst n = 13,135 vs cleavage stage n = 
41,110) revealed a comparable risk between groups (OR 0.97, 95% CI 0.81 – 1.15, p = 0.70, I2 = 
0%) (Supplemental data 2). 
 
Perinatal mortality 
Perinatal mortality was assessed in 3 studies (Ginstrom Ernstad et al., 2016; Dar et al., 2013; 
Martin et al., 2012) (blastocyst n = 8,458 vs cleavage stage n = 36,003). The overall OR did not 
differ between blastocyst and cleavage-stage pregnancies (OR 1.43, 95% CI 0.94 – 2.17, p = 0.10, 
I
2 
= 25%).  
Subgroup analysis of fresh cycles (blastocyst n = 6,665 vs cleavage stage n = 30,001) did not show 
any differences between groups (OR 1.35, 95% CI 0.95 – 1.92, p = 0.09, I2 = 0%) (Supplemental 
data 3).  
 
Congenital anomalies 
Congenital anomalies were addressed in 4 studies (Dar et al, 2013; Martin et al., 2012; Ginstrom 
Ernstad et al., 2016; Oron et al., 2015) (blastocyst n = 8,737 vs cleavage stage n = 36,097). 
Analysis of the overall effect size did not reveal any differences after blastocyst vs cleavage stage 
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transfer (OR 0.98, 95% CI 0.84 – 1.13, p = 0.73, I2 = 0%). Subgroup analysis of fresh cycles 
(blastocyst n = 6,944 vs cleavage stage n = 30,095) showed a comparable risk between blastocyst 
and cleavage stage (OR 0.99, 95% CI 0.84 – 1.17, p = 0.95, I2 = 0%). (Supplemental data 4).  
 
Risk of bias across studies  
We found no publication bias in terms of primary outcomes (Supplemental data 5): preterm birth 
(Egger‟s test, p = 0.47), or low birth weight (Egger‟s test, p = 0.77). 
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1.d  Discussion  
Summary of evidence 
Recent systematic reviews comparing perinatal and neonatal outcomes in singleton pregnancies 
from cleavage stage embryos and blastocysts raised relevant concerns about the safety of extended 
embryo culture in IVF (Maheshwari et al., 2013; Martins et al., 2016; Dar et al., 2014). According 
to the latest meta-analysis, blastocyst pregnancies are associated with an increased risk of preterm 
births, very preterm births and LGA deliveries, and a reduced risk of SGA was observed in 
blastocyst pregnancies (Martins et al., 2016). Comparing with previous meta-analysis (Martins et 
al., 2016), we used odds ratio instead of risk ratio given the retrospective design of studies included. 
Furthermore, we merged fresh and frozen cycles data from Ginnstrom Ernstad et al. (2016) and 
Ishihara et al. (2014) as reported by Chambers et al. (2015) and Fernando et al.(2012). Finally, we 
provide for the first time information regarding perinatal outcome differences between blastocyst vs 
cleavage stage embryo transfer in fresh cycles. 
Our results regarding fresh cycles are consistent with Martins et al. (2016) in terms of preterm 
birth, very preterm birth and SGA. However, when we included frozen/thawed cycles in our 
analysis, there were no differences in terms of preterm and very preterm births between blastocyst 
and cleavage stage pregnancies (Figures 1 and 2). Our results are in line with Chambers et al. 
(2015) who observed a higher odds of preterm birth in fresh cycle (OR 1.02 95% CI 0.94 – 1.11) 
compared with frozen cycles (OR 0.98 95% CI 0.94 – 1.11). A clear trend toward a higher risk of 
preterm births in fresh compared with frozen/thawed was confirmed by Ginstrom Ernstad et 
al.(2016).  In fact, both fresh blastocyst or cleavage stage cycles showed a higher risk of preterm 
birth than frozen blastocyst and cleavage stage cycles respectively (7.8% fresh blastocyst vs 6.5% 
frozen blastocyst p = 0.09; 7.2% fresh cleavage stage vs 5.2% in frozen cleavage stage, p< 0.05).  
Conversely, LGA risk appeared significantly different between blastocyst and cleavage stage 
embryo in fresh plus frozen/thawed cycles but not in only fresh cycle (Figure 6). Even this 
observation is supported by previous studies, which demonstrated a higher incidence of LGA in 
frozen/thawed cycle than fresh cycle (Pinborg et al., 2014). 
SGA risk between groups seems not to be not influenced by frozen embryo transfer with significant 
reduction in cleavage stage comparing with blastocyst transfer in both fresh and frozen/thawed 
cycles. Regarding the effect of frozen/thawed cycles on SGA, data in literature are contradictory, 
with some authors who observed a reduced incidence after frozen embryo transfer comparing with 
fresh transfer (Kato et al., 2012) and others who detected negligible differences (Sazonova et al., 
2012). 
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With respect of perinatal mortality we did not observed a significant risk in blastocyst pregnancy 
versus cleavage stage in both fresh and fresh plus frozen/thawed cycle population. Similarly, the 
risk of low birth weight, very low birth weight and congenital anomalies seemed to be not 
influenced by embryo cryopreservation procedure. 
Our finding concerning congenital malformations appears in contrast with previous reports of a 
higher risk of this condition after blastocyst transfer (Kallen et al., 2010; Dar et al, 2014). This 
discrepancy may reflect the improvements made in IVF techniques and embryo culture media 
(Ginstrom Ernstad et al, 2016). Indeed, data coming from the same register throughout time showed 
that the higher risk of congenital malformations after blastocyst transfer reported by Kallen et al. 
(2010) disappeared in a subsequent study conducted by Ginnstrom Ernstad et al. (2016). 
The safety profile of extended embryo culture is a matter of importance in clinical practice given 
the increasing use of this strategy in IVF centres of all world. Although, the risk of preterm birth 
and very preterm birth could be a cause of concern, the transfer of embryos at blastocyst stage has 
relevant advantages: higher implantation rate, the opportunity to select the most viable embryos 
avoiding transfer failure; better synchronization between endometrium and embryos at the time of 
transfer (Practice committees, Fertil Steril, 2013). Furthermore, extending embryo culture could 
favour a single embryo transfer policy, which is recommended to ensure live births for infertile 
couples and to reduce the risk of multiple pregnancies (ASRM, Fertil Steril, 2012). Furthermore, 
the fact that frozen/thawed cycles could some mitigate the adverse effect on perinatal outcomes 
could encourage cryopreservation in common clinical practice. This strategy offers the advantage of 
reducing ovarian hyperstimulation syndrome and gives the opportunity to limit the number of 
controlled ovarian stimulation. 
 
Limitations 
A limitation of this study is the low quality of data available. In fact, only retrospective studies are 
available. Furthermore, although an effect of cryopreservation is appreciable in our study, only 
specific meta-analysis comparing fresh with frozen cycles could definitely confirm if our 
observation are in the right direction. In addition, the definition of SGA and LGA deliveries is not 
consistent, and depend largely on the type of growth chart (Chambers et al., 2015; Ishihara et al., 
2014), ethnic and racial characteristics and on the cut off values adopted. Finally, we were unable to 
determine whether the type of culture affected our results.  
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1.e  Conclusion 
In fresh cycles, the risk of preterm and very preterm births was significantly higher after blastocyst 
transfers comparing with cleavage stage embryo transfer. However, both risks are comparable 
between groups when frozen/thawed cycles are included. Conversely, while no differences were 
observed in fresh cycles, LGA births were more frequent after blastocyst transfer than after 
cleavage stage transfer in fresh plus frozen/thawed cycle. SGA deliveries were significantly lower 
after blastocyst than cleavage stage transfer both in fresh and in fresh plus frozen/thawed cycles. No 
differences in terms of low birth weight, very low birth weight, perinatal mortality and congenital 
anomalies were observed between blastocyst and cleavage stage pregnancy in both fresh and 
frozen/thawed cycles. Caution should be exercised in interpreting these findings given the low level 
of evidence available and wide heterogeneity of studies. 
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Fig. 2 Forrest-plot for preterm birth.  
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Fig. 3 Forrest-plot for very preterm birth.  
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Fig. 4 Forrest-plot for SGA. 
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Fig. 5 Forrest-plot for LGA. 
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Supplemental data 1: Forrest-plot for low birth weight. 
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Supplemental data 2: Forrest-plot for very low birth weight. 
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Supplemental data 3: Forrest-plot for perinatal mortal 
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Supplemental data 4: Forrest-plot for congenital anomalies. 
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Supplemental data 5: Funnel plot and trim and firm analysis. 
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2. SYNOPSIS GENACOS 
 
Clinical Trial Protocol Number GENACOS 
Short Title Impact of Gonadotropin GENetics Profile and 
OvArian Reserve on Controlled Ovarian 
Stimulation Outcomes 
Full Title A multicentre, longitudinal, cohort, 
interventional (venipuncture), non-
pharmacological study to evaluate the impact of  
gonadotropin genetics together with ovarian 
reserve on the clinical outcome of IVF in 
infertile normo-gonadotropic women treated 
according to clinical practice  
Trial Phase Investigator Sponsored Interventional non-
pharmacological Trial 
EudraCT Number  
Coordinating Investigator& Sponsor Enrico Papaleo 
IRCCS San Raffaele Hospital, Milan, Italy 
Scientific Responsible Carlo Alviggi 
“University “Federico II”, Naples, Italy 
Clinical centers  Centro Scienze della Natalità, Ob-Gyn Dept., 
San Raffaele Hospital, Milan, Italy. 
 Dipartimento di Neuroscienze, Scienze 
Riproduttive ed Odontostomatologiche”, 
University “Federico II, Naples, Italy  
 ANDROS Day Surgery Clinic, Reproductive 
Medicine Unit, Palermo, Italy 
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 Clinica Zucchi - Biogenesi 
Centralized Laboratory Prof. Manuela Simoni 
Unit of Endocrinology, Department of 
Biomedical, Metabolic and Neural Sciences, 
University of Modena and Reggio Emilia, Italy 
Azienda USL of Modena, Italy 
Statistician Dr. Daniele Santi 
Unit of Endocrinology, Department of 
Biomedical, Metabolic and Neural Sciences, 
University of Modena and Reggio Emilia, Italy 
Azienda USL of Modena, Italy 
Scientific advisor Prof. Kypros Nicolaides 
King’s College – London, UK 
Equipment required E8 expert HD live with sonoAVC, v-SRI, 
crossXbeam, HDflow, VCI with omiview + 
High resolution 4D transvaginal probe Referent 
for ultrasound   procedure standardization and 
data managment: 
 Dr Floriana Carbone, MD, PhD – Research 
Fellow-Fetal Medicine Foundation – UK 
Planned trial period 
(first subject in-last subject out) 
2 years of data collection 
 
 
 
105 
 
2a.  Objectives 
The main objective of this study is to develop a predictive algorithm, based on Patients Ovarian 
Reserve (estimated through AFC = antral follicle count) and gonadotropin genetic profile, to 
define the personalized gonadotropin dose for controlled ovarian stimulation during Assisted 
Reproductive Techniques. 
Infertile female patients with normal ovarian reserve (OR) will be treated according to clinical 
practice and the difference between expected (through AFC) and retrieved oocytes will be 
assessed in relation to gonadotropin genetic profile. 
 
2b.  Scientific Background 
The number of oocytes collected remains the key prognostic marker in women undergoing 
Assisted Reproduction Technologies (ART), and growing evidence shows that an optimal – 
rather than a maximal – oocyte yield is the preferred achievement after controlled ovarian 
stimulation (COS) when fresh embryo transfer is scheduled. In fact, live birth rates steadily 
increase when six to fifteen oocytes are retrieved, while further hyper-response is associated 
with lower implantation rates, increased obstetrical risks and increased risk of OHSS in the 
fresh cycle (Verberg et al., 2009; Sunkara et  al., 2011; 2015). 
Criteria to select the proper starting dose of FSH have not yet been identified (Farquhar et al,. 
2014). If no previous cycles have been performed, the choice will be based on criteria as 
women's age and markers of ovarian reserve. On these bases different algorithms have been 
proposed, having demographic, anthropometrics and ovarian reserve indicators as independent 
variables and the number of retrieved oocytes as endpoint  (Howles et al., 2006; La Marca et al., 
2012). Despite promising results, these algorithms have been developed in retrospective 
analyses of limited series and need to be validated in adequately sized prospective studies.  
Although the “concept” of ovarian reserve dramatically changed the approach to COS, both 
hormonal and functional biomarkers do not allow a perfect personalization of therapies in IVF 
cycles for every patient, as it has been demonstrated that some patients can have a hyper-
response when stimulated with very low quantity of drugs and hypo-response in case of 
stimulation with high dosages of gonadotropins. The explanations for this discrepancies fall in 
two theoretical categories. The first is related to the relevant variability of ovarian reserve tests. 
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In particular, AMH measurements are associated with high inter-assay variability, whereas AFC 
shows limits in terms of inter-operator interpretation. These potential biases could affect both 
development and use of algorithms. In this scenario, moving from “subjective” to “objective” is 
crucial. Recently, it has been proposed the use of ultrasonographic automated- 3D follicular 
count to improve inter-reliability in AFC. This idea moved from the evidence that manual 
measurement of follicles with 2D ultrasonography (US) is often inaccurate and “time 
consuming”. Furthermore, it is associated with a degree of measurement error as follicles can be 
missed or counted more than once. It has recently suggested that the Automatic Volume 
Calculation (AVC), a software that identifies and quantifies hypoechoic regions within a 3D 
dataset and provides automatic estimation of their absolute dimensions, mean diameter and 
volume, may represent a valid alternative to standard 2D evaluation. Several studies 
demonstrate that AVC significantly improves the inter-observer reliability of AFCs and also 
provides highly reliable measures of number and the size of antral follicles when compared with 
standard 2D evaluation (Scheffer et al., 2002; Raine-Fenning et al., 2007; Jayaprakasan et al., 
2008; Raine-Fenning et al., 2008; Deb et al., 2009; 2010; Ata et al., 2011). 
The second potential limit of algorithms which are only based on ovarian reserve is that they did 
not include genetic characteristics of patients. Lessons from last decade clearly indicate that 
women with similar demographic, anthropometric and gonadotropin profiles may have 
dramatically different ovarian reserve. Nevertheless, there is also evidence that, even in 
presence of similar ovarian reserve, the “sensitivity” of follicles to exogenous FSH can differ. 
For instance, two women having the same AFC may display diverse Follicular Output RaTe 
(FORT [Genro et al., 2011]), meaning a different percentage of follicles reaching maturity with 
a given FSH dose. Follicular sensitivity to exogenous FSH may be related to a a “poly-genic 
trait”. This hypothesis is supported by studies correlating ovarian response to gonadotropins 
with the analysis  of polymorphisms (genetic variants whose frequency is higher than 1%) of 
gonadotropins and their receptors. The majority of the studies were focused on the single 
nucleotide polymorphisms (SNPs) of  FSH receptor gene (FSHR) and in particular on two 
substitutions of exon 10. The first SNP (rs6165) determines the nucleotide change (at position 
919) of adenine with guanine and the consequent amino acid substitution of  threonine with 
alanine, at codon position 307 (Thr307Ala). The second SNP determines  the nucleotide change 
(at position  2039) of  adenine with guanine, leading to the amino acid substitution of asparagine 
with serine at position 680 (Asn680Ser) (Aittomaki et al., 1995). These polymorphisms are in 
linkage disequilibrium. There is an increasing body of evidence suggesting that carriers of 
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680Ser show “hypo-sensitivity” to gonadotropin and require higher doses of exogenous FSH to 
achieve adequate ovarian response to COS (Behre et al., 2005).  
More recently, another polymorphism in the promoter region of the FSHR, in position -29, was 
identified (Wunsch et al., 2005). This polymorphism is characterized by the substitution of 
guanine with adenine (GGAA in GAAA) and it seems to reduce the expression of the FSHR. 
Our preliminary experience (data on file) suggest that carriers of this polymorphism also display 
reduced sensitivity to standard r-hFSH doses. 
The aim of this multicentre, longitudinal, cohort, interventional non-pharmacological study is to 
develop an algorithm for identifying the starting dose of r-hFSH by evaluating  the impact of  
gonadotropin genetics together with ovarian reserve on the clinical outcome of IVF in infertile 
normo-gonadotropic women treated according to clinical practice.  
This project introduces new crucial aspects with respect to previously reported models, 
including i) prospective design; ii) analysis of genetic aspects and iii) highly standardization of 
3D automated AFC. Finally, this study will also provide information on the impact all 
independent variable (including genetics and ovarian reserve) on the first stages of pregnancy. 
More specifically, they will be correlated with the outcome of first trimester screening. In fact, 
data in literature showed that conception by IVF is associated with increased risk for adverse 
pregnancy outcome (Chaveeva et all, 2010), such as early-preeclampsia (Carbone et all, 2011). 
The IVF procedure itself or the features of the subgroup of patients requiring IVF might affect 
the risk of obstetric and birth outcomes This study might lead to further understanding of the 
etiology and pathology of adverse obstetric outcome in these pregnancies. 
 
2c.  Methodology 
Multicenter, longitudinal, prospective, interventional, non-pharmacological cohort study, 
enrolling women attending clinical Centers of medically assisted reproduction (ART) with a 
normal ovarian reserve (the cohort).  
The study protocol consists in the record all the diagnostic and clinical outcome parameters, 
according to clinical practice,  for the following patients cohort: 
 Normo-gonadotropin patients (basal FSH ≤12 IU/L) with normal Ovarian Reserve (8 
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≤AFC≤ 16) that will be treated according to clinical practice with the following protocol; 
 14-21 days with contraceptive  
 r-hFSH treatment 150 IU/day for the whole stimulation period, starting from the 5rd day 
following contraceptive cessation (vs basal assessment day 2-3 of the cycle) 
 Gn-RH antagonist starting from day 6 of r-hFSH stimulation; 
 hCG triggering with at least two follicle >16 mm or GnRH-agonist triggering in case of risk 
of OHSS.; 
 Fresh embryo transfer. In case of OHSS risk and/or in case of progesterone rise on the day 
of hCG administration (≥ 2 ng/mL), all the embryos will be cryopreserved. 
Additional blood samples will be collected for gonadotropin genetic polymorphisms assessment 
and a serum sample for AMH, Estradiol (E2), LH and Progesterone (P4). 
Planned number of subjects: All subjects attending the Centers, in the study period, who match  
study inclusion criteria. At least 374 patients have to be enrolled. 
Primary endpoints: Number of retrieved vs. expected oocytes through AFC in relation to -29 
FSHReceptor (FSHR) Single Nucleotide Polymorphism (SNP). 
The AFC is measured with AVC and performed until the 5
th
 day in a natural cycle prior to the 
contraceptive cycle. 
Secondary endpoints:  
N° of follicles >10 mm; >12 mm; >14 mm; >16 mm; >18 mm; 
AMH ng/mL performed in a natural cycle prior to the contraceptive cycle; 
E2 level at basal, Day 5 and hCG day (centralized); 
LH IU/L, basal, day 5 and hCG day (centralized); 
Progesterone ng/mL on the hCG day (centralized); 
r-hFSH  dose (IU) /oocytes; 
Duration FSH treatment; 
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% of mature oocytes; 
Fertilization rate; 
Number of embryos developed, transferred and cryopreserved; 
Implantation Rate; 
Pregnancy Rate per started cycle;  
Pregnancy rate per embryo transfer; 
Ongoing pregnancy rate per started cycle. 
Endpoints I trimester:  
Rate of chromosomal abnormalities; 
Rate of early preeclampsia; 
Rate of small for gestational age;  
Association analysis with additional SNPs : FSHR680; LHR291; FSHB-211; v-beta LH. 
 
Inclusion Criteria:  
First stimulation cycle; 
Second stimulation cycle with “normo-response” to previous COS; 
Caucasian women; 
Eumenorroics normo-gonadotropic women;  
34≤ Age ≤39; 
basal FSH ≤12 IU/L; 
Ovarian Reserve between  8≤AFC≤16; 
Body Mass Index; 18≤ BMI ≤27; 
IVF/ICSI indication; 
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SmPC drugs criteria. 
ExclusionCriteria:  
Ovarian cyst > 12 mm the day of the beginning of COS; 
PCOS according to Rotterdam; 
POR according to ESHRE Criteria;  
Second stimulation cycle; 
Endometriosis III-IV stage; 
Intervention: Gonadotropin Genetic Profile (FSHR-29;FSHR680; LHR291; FSHB-211- v beta 
LH). 
Reference therapy dose/mode of administration/dosing schedule: None. 
Planned trial and treatment duration per subject: From initial visit until the end of assisted 
reproductive technique into two years of study. 
Statistical methods 
Several studies evaluated follicle stimulating hormone receptor (FSHR) gene in vitro activity, 
considering the single nucleotide polymorphisms in the promoter region of the gene (position -
29) (rs134205). They found that transcriptional activity of the A allele was 56+8% of that 
observed for the G allele. In particular, Desai et al. found a significant reduction in relative 
FSHR mRNA expression for the A/A genotype in 100 women attending assisted reproductive 
techniques. Considering the dominant model for the FSHR gene polymorphism, they found a 
relative FSHR mRNA expression of 0.12 for G/G allele, 0.07 for G/A and 0.02 for A/A. Thus, 
power analysis was performed (by G*Power software, version 3.1.9.2) assuming a variation of 
0.075 of relative FSHR mRNA expression produced by two genotypes. Difference between two 
independent means was considered as statistical analysis, α error probability was set at 0.05 and 
allocation ratio of 0.89, considering previous observational study . Considering a statistical 
power of 95%, the sample size is 164 women for first group and 148 women for second one. 
The total number of at least 374 women to be observed, considering a drop-out rate of 20%. 
Kolmogorov-Smirnov test will be used for valuation of parameters‟ distribution. Mann-Whitney 
and Kruskall-Wallis tests will be used for comparison of non-parametric variables, whereas 
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ANOVA will be used for parametric ones.  
Main parameter of this study will be the number of retrieved oocytes and this parameter will be 
compared to AFC, gonadotropin doses and genetic profile. The variables predictive of the 
number of retrieved oocytes will be assessed by backwards stepwise multiple regression. 
Backward selection of parameters will be applied, using Wald p<0.05 for entry and p>0.1 for 
removal. The variables reaching the statistical significance in multivariate regression analysis 
will be used in the calculation for the model elaborated in order to find the predictive algorithm. 
This algorithm will be implemented evaluating the association between genotype and response, 
creating dominant and recessive haplotype models, according to genotypes frequency. 
Statistical analysis will be performed using the „Statistical Package for the Social Sciences‟ 
software for Macintosh (version 20.0; SPSS Inc., Chicago, IL). Genotypic association tests 
assuming codominant, dominant, recessive, overdominant or log-additive genetic models will 
be performed using SNPstats. Linkage disequilibrium will be evaluated using SNPStat. 
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